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Osteoarthritis (OA) is one of the most common chronic musculoskeletal diseases of 
the joints and is characterized by degradation of the articular cartilage as well as hypertrophy 
of the bone. This leads the clinical symptoms of pain, joint stiffness, loss of mobility, and 
functional impairment. OA affects 33.6% of those 65 years of age and older in the United 
States [1]. In addition to effecting older populations, OA is also prevalent in young 
populations as a resultant of injuries and is termed post-traumatic OA. Current treatments of 
OA include non-steroidal anti-inflammatory drugs, corticosteroid injections, and hyaluronic 
acid injections. These therapies are targeted towards pain relief and have little to no disease-
modifying activity. The following work explores three different therapeutic methods that 
seek to modify the disease state of OA: 1) Clearance of senescent cells (SCs) by senolytic 
compounds, 2) Urinary bladder matrix biomaterial injections, and 3) Hyaluronic Acid 
Binding Peptide (HApep)-polymer system injections.  
The first therapy focuses on cellular senescence, which are known to be associated 
with age-related disorders such as OA. This work further explores the relationship between 
SC and OA and how eliminating SCs can reverse OA-related aging of the joint. It was found 
that SC negatively affects the chondrogenic potential of stems cells and that senescent 
chondrocytes can effect matrix production of healthy chondrocyte populations. Furthermore, 
it was found that the selective clearance of SC with Nutlin-3a senolytic increased cartilage 
matrix formation and reduced symptomatic pain in post-traumatic OA mouse model. The 
second therapy that was explored involved injection of UBM, which contains many 
biofactors and proteins that can encourage regeneration, into the intra-articular space. Results 
showed improvement in pain outcomes and also decreased amount of cartilage lesions and 
proteoglycan loss. Lastly, the injection of a HApep-polymer system was evaluated with the 
intention of increasing the retention of HA into the joint and improving the efficacy of 
current HA treatments and it was found that this also decreases cartilage degradation and 
improved pain outcomes. The three therapies presented in this thesis represent viable 
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Chapter 1: Introduction to Thesis 
1.1  Osteoarthritis 
Osteoarthritis (OA) is a chronic musculoskeletal disease of the joints that affects 33.6% 
of those 65 years of age and older in the United States [1]. OA of the knee joint in particular is 
the most prevalent, leading to disability in 1 out of 5 of institutionalized adults [1]. In the 
healthy state (Fig.1.1), the tibial and femoral surfaces of the knee joint are covered by 
articular cartilage tissue that is composed of collagen II, proteoglycans, chondrocytes and has 
a highly organized matrix structure that imparts viscoelastic characteristics to facilitate in 
biomechanical load-bearing [2]. Chondrocytes are the primary cell type in articular cartilage 
and they are responsible for the formation and maintenance of articular cartilage [3]. In OA 
(Fig 1.1), the articular cartilage of the joint degrades and is accompanied by thickening of the 
subchondral bone, synovial inflammation, and osteophyte formation due to imbalance of 
biological molecules that disrupt homeostasis [4]. This leads to clinical symptoms of pain, 
joint stiffness, loss of mobility, and functional impairment [2].  
Risk factors for OA include traumatic injuries, most common in military populations with 
60% of wartime injuries leading to arthritis [5,6]. High level of injury-related impact energy on 
the articular surface can causes post-traumatic OA (PTOA) by damage to chondrocytes and 
the surrounding matrix structure resulting in loss of proteoglycan content and cartilage 
fibrillation eventually leading to functional impairment [3,7]. Military populations have a 
higher incidence of OA compared to general populations majorly due to injury from land 
mines, blast waves, explosive ordnance, vehicle crashes, and other forms of combat [8]. 
Another source of OA in military personnel is service-related overuse caused by physically 
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demanding exercise regimes and performance in extreme environments leading to load 
bearing beyond the physiological range [9]. In addition, sports that involve a higher intensity 
of joint impact and torsional loading, such as soccer and lacrosse, also can cause injuries that 
lead to PTOA [3].  
Another risk factor for OA is natural aging. Age-related OA is caused by molecular, 
mechanical, and structural changes in the articular cartilage matrix. Human chondrocytes, the 
primary cell type in cartilage, have decreased production of proteoglycan and aggrecan 
molecules [10]. Cellular senescence is also a hallmark of aging that is related to OA and 
involves loss of proliferative potential and expression of the senescent-associated secretory 
phenotype (SASP) that includes production of growth factors, cytokines, proteases, and other 
proteins. [11]. Chondrocyte senescence is proposed to be resultant of chronic stress, and cells 
isolated from older patients have been shown to produce more pro-inflammatory factors such 
as matrix metallopeptidases (MMP) like MMP13 and MMP3 and interleukins (IL) such as 
IL-1 [12]. This inflammatory environment of the OA knee joint also causes the synovial fluid 
(SF) between the joints to become less viscous due to degradation of hyaluronic acid (HA), 
which affects the ability to provide effective shock absorption and lubrication [13]. Cellular 
senescence and decreased joint lubrication are part of a viscous cycle that leads to reduced 
cartilage tensile strength and stiffness and causes fibrillation and thinning of the surface with 
age [10,12] (Fig.1.2).   
1.2  Current Strategies for Treatment 
Current treatments for OA range depending upon the severity of the disease. The mildest 
form of treatment includes lifestyle changes such as weight loss and exercise. Another form 
of treatment is systematic analgesic medication that includes acetaminophen, nonsteroidal 
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anti-inflammatory drugs (NSAID), and COX2 inhibitors [2]. These only temporarily relieve 
pain, and often lead to other complications such as gastrointestinal bleeding. In addition, the 
focus of these current drug-based treatments is also on pain relief as they lack structural-
modifying efficacy. There is a lack of disease modifying anti-OA drugs and current 
development of these types of drugs is focused on targeting the articular cartilage tissue [2].  
For a more progressed form of OA, treatment options include HA and corticosteroid 
injections into the intra-articular (IA) space. One primary drawback of HA injections are that 
they have a short residence time due to degradation by native enzymes (t1/2=24 hours) [14]. 
Corticosteroid injections also have limitations including injection site complications, such as 
leakage, and the focus on relieving pain rather functional restoration [15].  
More severe forms of interventions include biomaterial treatments, still majorly in the 
research stage, and total joint replacement [2]. An example of biomaterial treatment currently 
in research phase includes injection of extracellular matrix (ECM) intra-articularly. Proteins 
in ECM have been shown to have regenerative applications and therefore could have disease-
modifying ability, but much research still must be done in this area [16]. 
1.3  Specific Aims of Thesis 
The multifaceted nature of OA calls for research into a variety of different modalities to 
successfully be able to treat the disease. The presented work will explore three different 
therapeutic strategies addressing limitations of current treatments, with the combined goal of 
assessing clinical potential through disease-modification by targeting the articular cartilage 
tissue and systematic pain relief: 
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Specific Aim 1: Further investigate the relationship between the presence of senescent 
cells on the healthy joint environment and how this can be attributed to OA. In addition, 
determine if use of a senolytic drug to clear senescent cells has disease-modifying 
capability using a preclinical small animal model of PTOA. 
 
Specific Aim 2: Determine if particulate ECM injected IA into a preclinical small animal 
model of PTOA has disease-modifying ability and can be used as a treatment for OA.  
 
Specific Aim 3: Utilize a hyaluronic acid binding peptide system to increase the retention 
of HA in the IA space and determine the therapeutic efficacy in a preclinical small animal 
model of PTOA.  
1.4  Figures 
 
Figure 1.1 Healthy vs. OA State of the Knee Joint [17]  
In the healthy joint, the articular cartilage acts as a load-bearing surface, but degrades in the 




Figure 1.2 Viscous Cycle of OA [2] 
There are many risk factors for OA that together create multiple pathophysiological 
processes such as cartilage matrix degradation and reducing viscosity of synovial fluid that 
eventually lead to joint destruction and clinical symptoms. 
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Chapter 2: Senescent Cell Promotion of Cartilage Degradation 
and Clearance of Senescent Cells Prevents Development of Post-
Traumatic Osteoarthritis  
 
2.1 Introduction  
2.1.1 Senescent Cells  
Biological aging, termed senescence, was first observed on cells by Hayflick in the 
1960s when he showed that cells have a limited number of divisions, and the number of 
divisions decrease with age of the donor [1]. Cellular senescence plays an important role in 
tumor suppression, wound healing, tissue repair, embryonic development, and aging [2]. In 
wound healing specifically, senescent cells (SCs) secrete platelet-derived growth factor AA 
(PDGF-AA) that promotes repair and reduces excessive fibrosis [3].  
SCs involve an irreversible growth arrest that occurs due to external and internal 
stimuli and stresses, but differ from other types of non-dividing cell types [4]. Stress-inducing 
stimuli include telomeric DNA loss at the S stage, genomic damage at non-telomeric sites, 
mitogenic signaling, and hyperphysical cultural stresses, all of which lead to a DNA damage 
response (DDR) [4]. Although there are no specific markers for SC, the stresses cause 
activation of signaling networks, which ultimately lead to expression of p53 tumor 
suppressor, p21WAF1, and p16INK4a factors which retain the senescent phenotype [2,4]. Cells 
that are in a temporal arrested state then transition to a senescent state by an unknown 
mechanism [2]. A detailed pathway of how stress leads SC can be seen in Fig. 2.1.  
Other characteristics of the senescent phenotype include larger cellular size, 
expression of senescence-associated beta-galactosidase (SA-β-gal), persistent nuclear foci, 
and a senescent secretome termed the senescent-associated secretory phenotype (SASP) [4]. 
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The SASP involves a robust secretion of cytokines, growth factors, proteases, and other 
proteins that lead to alterations in biological processes that are related to paracrine signaling 
such as tissue repair, angiogenesis, cellular proliferation, wound healing, and inflammation 
[2,4]. The composition of SASP components has plasticity across different types of cells and 
stress inducers [4] but it is known that some proinflammatory cytokines and chemokines are 
conserved between different cell types suggesting possible role of SCs in inflammatory 
response [2]. Although SCs may recruit immune related factors, the accumulation of SCs does 
not always coincide with immune cell infiltration and inflammation [2]. Based on all these 
characteristics of the SC phenotype, current methods to detect SC include high levels of 
p16INK4a, p21Waf1, IL-6, and SA-β-gal activity [2]. 
2.1.2 SCs Accumulation in Age-Related Osteoarthritis   
It is known that SCs accumulate in tissues in the body that are associated with aging 
in chronic conditions such as OA, Alzheimer’s, pulmonary fibrosis, and atherosclerosis [5,6,7]. 
During processes such as embryogenesis and repair, SC clearance is temporally controlled 
and efficient however in age-related diseases it is believed that deterioration of the immune 
system with age allows for SC accumulation [2]. Evidence of the connection between age-
related diseases and senescence has further been explored by experiments done in targeting 
p16Ink4a positive SC in BubR1 progeroid mice [2]. In these experiments it was shown that 
genetically inactivating p16Ink4a prevents SC development and consequently reduced the 
onset of age-related diseases in the skeletal muscle, eye and fat tissues [2].  
The relationship of how SCs are related to the progression of disease-related aging 
remains unknown [2]. One speculation is that cellular senescence causes a decrease in the 
regenerative potential of tissues and that the SASP acts on the local stem and progenitor cell 
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environments [4]. Another theory is that the SASP effects cellular growth, migration, and 
differentiation thus leading to disruption in tissue structure and function [4]. Lastly, it is 
believed that cytokines in the SASP lead to chronic inflammation and production of oxidants 
[4].  
In OA in particular, the accumulation of SCs in the knee joint, mostly senescent 
chondrocytes, and the associated SASP further promote the disease pathology [6]. In general, 
chondrocytes in OA have declined mitotic and synthetic activities and make smaller aggrecan 
molecules and less functional link proteins [8]. Chondrocyte senescence may be due to 
chronic stresses generated in the local environment such as mechanical loading that induces 
cellular oxidative damage [8] and cytokine stimulation that causes DNA damage and 
subsequently telomere shortening [9]. Known SASP factors of senescent chondrocytes include 
matrix remodeling metalloproteases MMP3/MMP13 and pro-inflammatory cytokines 
interleukin-8 (IL-8), IL-6, and IL-1β [9,10]. It is believed that these factors compromise 
cartilage integrity due to decrease in anabolic activity [10].  
2.1.3   SCs Accumulation in Post-Traumatic Osteoarthritis   
Chronic stresses such as mechanical loading and cytokine stimulation can cause also 
lead to PTOA in addition to age-related OA. Validation of SC accumulation in PTOA was 
conducted previously in the Elisseeff Lab through use of a p16-3MR transgenic mouse model 
of PTOA induced by anterior cruciate ligament transection (ACLT). The p16-3MR 
transgenic mice contain a bacterial artificial chromosome with the p16 INK4a promoter that 
drives expression of the tri-modal reporter (3MR) (Fig.2.2a) to encode a fusion protein that 
has Renilla luciferase (rLUC) to visualize SCs through luminescence [11]. Expression also 
drives the production of monomeric red fluorescent protein (mRFP) for sorting of SCs from 
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tissue samples and a herpes simplex virus thymidine kinase (HSV-TK) for selectively killing 
of p16INK4a-expressing cells through administration of ganciclovir (GCV) that TK converts 
into a toxic DNA chain terminator and fragments mitochondrial DNA to induce apoptosis in 
SCs  [11].  
Measurement of luminescence through use of the rLUC fusion protein showed 
accumulation of SCs (Fig. 2.2b) and an increase in gene expression of p16INK4a (Fig. 2.2c) in 
the knee subject to ACLT. Additionally, the maximal accumulation of SCs, determined by 
luminescence and p16INK4a was observed to be two weeks after ACLT surgery. These results 
confirm that ACLT induces accumulation of SCs in the joint environment, thus providing a 
connection between PTOA and SCs.  
2.1.4 Clearance of SCs to Treat Age-Related Diseases  
As people age, they become more susceptible to chronic diseases that lead to frailty 
and loss of independence both of which limit healthy lifespan and the ability to live 
independently [12]. Current treatments for chronic conditions primarily focus on treating 
downstream symptoms, but do not target the cause of age-related diseases [12]. The 
mechanisms of aging are largely unknown, and thus it remains difficult to develop 
interventions to delay onset of age-related diseases [7].  Studies done in BubR1 mice have 
shown accumulation of SC in mice, and furthermore that inducing apoptosis of the 
accumulated SC in the mouse model with an administration of synthetic drug results in 
reduced onset of age-related diseases in the skeletal muscle, eye and fat tissues [7]. This 
suggests that elimination of SC could be a possible therapeutic strategy for treating age-
related diseases [2]. Having mechanism-based treatments can make “aging a modifiable risk 
factor” [12].   
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There are a few strategies that can be employed to selectively eliminate SC and their 
SASP. One strategy includes developing antibodies to target SC through epitope recognition 
[12]. Some limitations of this method include complete elimination of SC, which may not be 
necessary since SC have also been shown to have some positive effects, and difficulty in 
execution that has already been a problem in the cancer field [12].  Another approach that may 
be promising is use of a small molecule that can be developed using high-throughout screens 
in vitro [12].  
The effect of senolytic drugs has yet to be explored in context of OA. Since SC 
accumulate focally within the joint space in this disease, it is possible to inject senolytics into 
the IA space to determine how the drugs effect disease progression [12]. One possible class of 
small molecules that can be used are cis-imidazoline analogs, also called Nutlins, that are 
known to disrupt binding of the murine double minute-2 (MDM2) protein with tumor 
suppressor p53 [13]. Modulation of the p53 transcriptional activity activates p21Waf1 
downstream and leads to selective apoptosis of SC therefore can be potentially used 
therapeutically for clearance of SC [13,14].  
Provided herein are the methods and results of further investigation into how SC can 
affect cellular processes related to OA, specifically chondrogensis and cartilage matrix 





2.2  Materials and Methods  
2.2.1  Part A: SC Promotion of Cartilage Degradation 
Cell Isolation  
Human articular cartilage explant samples from OA or healthy patients undergoing 
total knee arthroplasty or post-modem were received from the National Disease Research 
Interchange (NDRI; Philadelphia, PA) according to an Institutional Research Board (IRB)-
approved protocol. Cartilage tissue was washed with phosphate-buffered saline (PBS) and 
then cut into 1mm3 pieces and washed 3 times with PBS supplemented with 100U/mL 
penicillin and 100μg/mL streptomycin (Pen/Strep). Cartilage pieces were then digested in 
collagenase solution (with 0.17% (w/v) type II collagenase (Worthington Biochemical, USA) 
in high-glucose Dulbecco’s modified Eagle’s medium (DMEM; InvitrogenTM, Life 
Technologies, USA) with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, USA) 
overnight on an shaker for 16 hours at 37°C. Filtrate was then passed through a 70uM 
strainer, centrifuged for 10 min at 1000rpm, and rinsed 3 times with PBS. Chondrocytes were 
cultured in chondrocyte growth medium composed of high-glucose DMEM supplemented 
with 10% FBS, 1% 100mM sodium pyruvate (GibcoTM, Life Technologies, USA), 1% 
Pen/Strep, 1% 10mM Non-essential amino acids (NEAA; InvitrogenTM, Life Technologies, 
USA), 1% 1M HEPES (GibcoTM, Life Technologies, USA), 0.2% 0.2M L-proline, (Sigma-
Aldrich, USA) and 0.2% 25mg/mL ascorbic acid (Sigma-Aldrich, USA). 
Human mesenchymal stem cells (hMSCs) were obtained from Dr. Arnold Caplan 
(Case Western Reserve University) and maintained in MSC growth medium composed of 
low-glucose DMEM supplemented with 2mM L-glutamine, Pen/Strep, 10% defined FBS, 
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and 1.0ng/mL basic fibroblast growth factor (FGF; PeproTech, USA). Cells from passages 3-
5 were used for all experiments.  
Mouse embryonic fibroblasts (MEF) were isolated from pregnant 3MR transgenic 
mice (Buck Institute for Research on Aging, Novato, CA). On the 12-13th day of pregnancy, 
mice were anesthetized with 3% isoflurane and sacrificed by cervical dislocation. Mice were 
sprayed with 70% ethanol externally and then abdominal skin was opened and body wall was 
washed with 70% ethanol. Uterus was removed and placed in Petri dish with PBS. Embryos 
were removed from the uterus, separated from the placenta, and surrounding membrane was 
then transferred and rinsed in a new dish. Internal organs and head were removed using 
forceps and discarded while embryos were placed into individual wells of a 24-well plate and 
washed 4 times with PBS. Embryos were then digested overnight in individual 15 mL 
conical tubes at 4°C with 1 mL 0.05% trypsin (GibcoTM, Life Technologies) then shaken 
vigorously to break up tissue and incubated at 37°C for 10 minutes. After incubation, 10mL 
of MEF medium (high glucose DMEM, 10% FBS, 1% NEAA, 1% Pen/Strep) was added to 
each embryo and mixed. Supernatant was transferred to dishes and incubated at 37°C/5%CO2 
for 3 days. P1-P2 primary MEF cells were used for all experiments.  
C57BL/6 cell line MEF cells (AATC, USA) were purchased and grown in MEF 
medium. P3-P5 cell line MEF cells were used for all experiments.  
 
Induction of SC by Irradiation  
Cells were allowed to fully attach to tissue culture plates before irradiation. Cell 
plates were exposed to x-rays for a specified amount of time depending upon dosage (0 
Grays=0 seconds, 10 Grays=161 seconds, 15 Grays=237 seconds, 20 Grays=314 seconds, 30 
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Grays=466 seconds, 40 Grays=600 seconds). Irradiation was administered via a CIXD 
Xstrahl machine (Xstrahl, United Kingdom) with dual x-ray tubes at a voltage of 220V and 
current of 13A. Cell medium was changed 1 hour after irradiation to remove detached cells. 
Cells were cultured for 10 days in normal culture conditions (37°C/5%CO2) after irradiation 
to allow for expression of SC phenotype before using for experiments [15].  
 
hMSC Pellet and Micromass Culture  
A 2D micromass culture system was applied as previously described [16]. Cells were 
harvested and suspended at 2x107cells/mL in chondrogenic medium composed of high 
glucose DMEM, 1% Pen/Strep, 1% 100mM sodium pyruvate, 1% ITS premix (6.25mg/mL 
insulin, 6.25 mg/mL transferrin, 6.25ng/mL selenous acid; BD Biosciences, USA), 0.2% 100 
nM Dexamethasone, 0.2%20 mg/mL L-proline, 0.2% 25mg/mL ascorbic acid, and 10ng/mL 
of transforming growth factor-beta 1 (TGF-β1; Fitzgerald Industries International, USA). 
Droplets (12.5μL) were placed into the center of each well in a 24-well plate and cells were 
allowed to adhere for 2 hours at 37°C/5%CO2. After, 0.5mL chondrogenic medium was 
added to each well and changed every 3 days. 2D micromass was kept in culture for 3 weeks 
at 37°C/5%CO2.  3D Pellet culture system was also applied as previously described [16,17]. 
hMSCs (400,000 cells) were seeded in the 96 well MicroWell™ round bottom plate (Thermo 
Fisher Scientific, USA) and the pellets were formed in the bottom by centrifuging at 150g for 
10 min. The pellets were maintained at 37°C/5% CO2 in 200μl of the chondrogenic growth 




Fluorescent-Activated Cell Sorting (FACS)  
Human articular chondrocytes isolated from OA patients were expanded until P3 
(~20 million cells) and sorted using FACS Aria IIu Sorter (BD Biosciences, USA) based 
upon size in FL1 and auto-fluorescence (488 nm) by FSC as previously described [18]. There 
are currently no known markers of SC for live sort; therefore the sort was based enlarged size 
and accumulated auto-fluorescence of the age pigment lipofuscin in SC [18]. The FSC/SSC 
dotplot of auto-fluorescence vs. size was then generated and used to set up gates to sort the 
chondrocytes into three groups to generate populations with different proportions of SCs. 
Live cells were sorted in buffer composed of PBS with 1% FBS and collected in chondrocyte 
medium with 2x Pen/Strep. 
 
Co-Culture  
A 24-well Corning® Transwell® plate with 6.5 mm inserts (Sigma-Aldrich, USA) 
was used for co-culture experiments.  Healthy chondrocytes (20,000/well) were seeded into 
each well. Sorted OA chondrocytes (20,000/insert) from FACS were then seeded onto the 
inserts. Cell were cultured for 1 week at 37°C/5%CO2 in chondrocyte growth medium.  
 
Bystander Effect  
 Healthy human chondrocytes (20,000/well) were seeded onto a 24-well plate. 
Conditioned medium from co-culture experiment groups (control, low, medium, high) was 
then added onto the cells after attachment occurred. Medium was changed once and cells 
were incubated at 37°C/5%CO2 for 1 week. 
 
17 
SA-β-Gal Staining  
SA-β-gal staining was performed using a SA–β-gal staining kit (catalog no. #K320-
250, Biovision, CA, USA) according to the manufacturer’s instructions. SCs were identified 
as green/blue-stained cells under light microscopy and counted. Total cells were counted 
using the DAPI staining for nuclear regions in 10 random fields on a culture dish to 
determine the percentage of SA-β-gal positive cells out of total cell population.   
 
Proteoglycan Staining for 2D Culture  
In vitro 2D cultures were stained for proteoglycans by adding 0.25mL of Safranin-O 
(0.1%, pH 5.6; Wards Chemical, USA) into each well for 5 mins and then washed with PBS 
3 times. In vitro 2D cultures proteoglycan content was also stained with alcian blue (3%, pH 
2.5; Sigma Aldrich, USA) for 30 mins then washed with PBS 3 times. Wells were then 
mounted and imaged under light microscopy.  
 
Human Antibody Array 
Cytokine antibody array was performed with a human cytokine array kit (R&D 
Systems, Catalog # ARY005) according to the manufacture’s instructions. Conditioned 
media for antibody array analyses were prepared by washing approximately 0.2 × 106 cells 
once with PBS, and incubating them in serum-free medium for 24 h. The conditioned media 
was collected in 1.5 ml centrifuge tube and centrifuged after which supernatant placed into a 
new tube. Each array membrane was incubated with 1.5ml of 3-fold diluted conditioned 
media overnight at 4°C, washed, and incubated with biotin-conjugated antibody cocktail, 
washed, then incubated with streptavidin-HRP conjugate and subsequently cytokines were 
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detected by Chemi reagent mix. The signals developed on the X-ray film were quantified to 
the average signal (pixel density) of the pair of duplicate spots representing each cytokine by 
Image J software (NIH, USA). The experiments were repeated in duplicate.  
  
Bioluminescence  
For in vitro luminescence imaging, 0.2μL per 1mL of PBS of Xenolight RediJect 
Coelentarazine h (150μg/mlCalipers, Waltham MA, USA) was added to well of cell culture 
plate. Fifteen minutes later, the luminescence was measured with a PerkinElmer IVIS 
SpectrumCT in vivo imaging System (Caliper Life Sciences, Hopkinton MA, USA; 5 minute 
exposure, medium binning). A region of interest (ROI) was constructed around each 
measurement well and a background ROI was constructed to subtract from each 
measurement.   
 
IA Injection  
C57BL/6 mice (Charles River, Germantown, MD) that were 6-months old 
anesthetized were 3% isoflurane. Intra-articular injections (10μL) of 2 million irradiated 
MEF cells (N=5), 2 million non-irradiated MEF cells (N=5), saline (N=5), and no injection 
(N=5) were performed on the right knee of the mouse with a sterile 30-gauge needle. All 
procedures were performed according to the Institutional Animal Care and Use Committee at 





Hot Plate Analysis  
Mice were placed on the hotplate at 55°C (Columbus Instruments, USA). The latency 
period for hind limb response (includes shaking, jumping, or licking) was recorded as 
response time before any surgical procedures and injections, and at periods of time after the 
surgical procedures and injections. At least three measurements are taken per mouse. The 
observer was blinded to the treatment group.  
 
Weight Bearing Analysis   
Static incapacitance measurements were performed using Incapacitance Tester 
(Columbus Instruments, USA). Before injection, mice were acclimated to the chamber at 
least 3 times before measurement. After, mice were maneuvered inside chamber to stand 
with each hind paw on a sensor. Weight placed on each hind limb is measured over a 3-
second time frame for at least 3 separate measurements. Results are expressed as a 
percentage of weight placed on the operated limb versus contralateral control. The observer 
was blinded to the treatment group. 
 
Histological Evaluation  
The pellets and knee joints were fixed in 4% paraformaldehyde overnight. Mouse 
joints were decalcified using 10% EDTA (Sigma Aldrich, USA) for 2-3 weeks. Successful 
decalcification was determined by using Calcium Colorimetric Assay Kit (BioVision, USA) 
according to manufacture’s instructions. Joints and pellets were then dehydrated in increasing 
concentrations of ethanol, infiltrated with xylene, and embedded with paraffin. Seven 
micrometer-thick sections were cut from the paraffin block and collected onto the glass 
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slides. The sections were stained for proteoglycans with aqueous Safranin-O (0.1%) for 5 
minutes and methyl green (Sigma Aldrich, USA) counterstain for 30 seconds then the 
specimens were mounted.  
For immunohistochemical (IHC) staining, endogenous peroxidase of the sections was 
quenched using 2.5% (v/v) hydrogen peroxide in methanol and then incubated at 37°C with 
0.25% (w/v) hyaluronidase for 1 h. AEC Broad Spectrum Histostain-SP Kit (Invitrogen, 
USA) was used following the manufacturer’s instructions. Primary antibodies for p16 INK4a, 
type II, and X collagen, osteocalcin (Abcam, USA) were used with a 1:500, 1:300, 1:50, 
1:100, dilution factor in 4% BSA dissolved in PBS.  
Histological assessment of the medial tibial plateau joint was then conducted through 
blinded graded observations by 2 observers, according to the Osteoarthritis Research Society 
International (OARSI) Scoring System. 
 
 RT-PCR Analysis  
To extract RNA from knee joints, the operated and control hind limbs were dissected 
and immediately transferred to liquid nitrogen and then pulverized with mortar and pestle 
and transferred to a micro centrifuge tube. Total RNA was extracted from the knee joints 
using the Trizol reagent and reverse transcribed to complementary DNA (cDNA) using 
Super-Script II reverse transcriptase following the manufacturer’s protocol (Invitrogen, 
Carlsbad, CA).  
To extract RNA from pellet samples, the samples were placed into a microcentrifuge 
tube and immediately transferred to liquid nitrogen before being pulverized in the tube with a 
pestle. Total RNA is then extracted from pellet samples and from monolayer cell cultures 
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using RNeasy Mini Kit according to manufacturer’s protocol (Qiagen, USA) and transcribed 
to cDNA using Super-Script II reverse transcriptase following the manufacturer’s protocol 
(Invitrogen, Carlsbad, CA).  
Real-time PCRs for selected genes were performed using StepOnePlus Real Time 
PCR System with the SYBR Green PCR Master Mix. All genes are normalized to β -actin. 
Mouse primers are listed in Table 1 and human primers are listed in Table 2. Relative gene 
expression was calculated by the ΔΔCt method where the ΔCt was calculated using the β-
actin reference gene.  ΔΔCt was calculated relative to the unoperated control group in in vivo 
studies and relative to control samples in in vitro studies.  
 
Statistics  
All data was statistically analyzed using one-way ANOVA with multiple comparison 
test in GraphPad Prism Software with an alpha value of 0.05 and 95% confidence interval 
with the exception of PCR data which was analyzed using unpaired t-test with Welches 
correction. *p < 0.05, **p<0.01, ***p<0.001 considered significant. 
 
2.2.2   Part B Clearance of SC Prevents Development of PTOA 
 
 
3D Chondrocyte Pellet Culture  
Human chondrocytes were isolated from OA cartilage as described in Section 2.2.1. 
3D Pellet culture system was also applied as previously described [17]. P1 OA Chondrocytes 
(400,000 cells) were seeded in the 96 well MicroWell™ round bottom plate (Thermo Fisher 
Scientific) and the pellets were formed in the bottom by centrifuging at 150g for 10 min. The 
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pellets were maintained at 37°C with 5% CO2 in 200μl of the chondrogenic growth medium. 
Pellets were harvested after 14 days for evaluation. The media was changed every two days.  
 
Surgically Induced PTOA model  
ACLT and sham surgery were performed on 10-week or 19-month old male 
transgenic p16-3MR mice (Buck Institute for Research on Aging, Novato, CA), 10-week old 
male C57BL/6 mice (Charles River, USA), and 10-week old male Sprague-Dawley rat 
(Charles River, USA) as previously described [19]. Ten-week old male mice were chosen 
because of skeletally maturity exhibited at that age and to avoid hormonal factors with 
female mice [19].   
To prepare for surgery, animals are placed under general anesthesia (3% isoflurane) 
and the hind limbs are shaved. Knee joint is exposed following a medial capsular incision 
and the ACL is transected with micro-scissors under surgical microscope. Open space is 
irrigated with saline to remove tissue debris and the skin incision is closed with sutures. The 
joint cavity was opened in the sham group but the ACL was not transected. All procedures 
were performed according to the Institutional Animal Care and Use Committee at Johns 
Hopkins University School of Medicine.  
 
IA Injection  
Intra-articular injections of 10μL of Nutlin-3a (1 mM), GCV (2mM), saline (vehicle), 
or #911(1mM, 300μM, 100 μM) were performed on the right knee of the mouse with a sterile 
30-gauge needle at the appropriate dosing regime (2 weeks post-ACLT, single or multiple 
23 
injections). All procedures were performed according to the Institutional Animal Care and 
Use Committee at Johns Hopkins University School of Medicine.  
 
Bioluminescence 
For in vivo luminescence imaging, the p16-3MR mice were injected intra-articular 
with 10μl (150µg/ml) of Xenolight RediJect Coelentarazine h (Calipers, Waltham MA, 
USA).  Mice were anesthesized (3% isofluorane) 25 min later and luminescence was 
measured with a PerkinElmer IVIS SpectrumCT in vivo imaging System (Caliper Life 
Sciences, Hopkinton MA, USA; 5 minute exposure, medium binning). A region of interest 
(ROI) was constructed around each measurement area and a background ROI was 
constructed to subtract from each measurement.   
 
Real time RT-PCR 
RT-PCR was done as described in Section 2.2.1. Primers were used as shown in 
Table 1 and 3.  
Hotplate analysis 
Hotplate analysis was done as described in Section 2.2.1.  
Weight bearing  
Weight bearing was done as described in Section 2.2.1. Rats were subject to the same 




Von Frey  
 Von Frey Filaments (Bioseb, USA) were used to perform static testing of pain 
tolerance based on paw withdrawal reflex in rats. Rats were placed on platform containing 
1.5 mm diameters holes for application of von Frey hairs. Monofilaments beginning from a 
stiffness of 10 up to a stiffness of 60 were applied to the plantar hind paw and the level at 
which the rat withdrew paw was measured. At least three measurements are taken per mouse. 
The observer was blinded to the treatment group. 
 
Histology  
Histology was done as described in Section 2.2.1. 
SA-β-Gal Staining  
SA-β-gal staining was done as described in Section 2.2.1. 
IC50 determination 
 Nutlin-3a was injected IA (5.8 μg/10μl) into two ACLT mice per time point (0, 0.25, 
0.5, 1, 2, 4, 8, 24 hours) with each mouse providing one sample for local concentration (knee 
joint extraction) and one sample for systemic concentration (blood sample) measurements. 
Pharmokinetic measurements and determination of half-maximal inhibitory concentration 
(IC50) was performed by Seventh Wave Laboratories (MO, USA).  
 
Microparticle Synthesis  
Nutlin-3a and ganciclovir (GCV) loaded microparticles were prepared using solvent 
evaporation method [20] as previously described. In brief, 20 mg of five-arm 50:50 
poly(lactic-co-glycolic acid) (PLGA; Sigma Aldrich, USA) was dissolved in 2 mL of 
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dichloromethane for 1 hour to form the organic phase. Nutlin-3a (2 mg), GCV (2 mg), or no 
drug was then added to the organic phase and allowed to dissolve and mix for 1 hour at room 
temperature. Organic phase was then added into 1% Poly-vinyl-alcohol (PVA; Sigma-
Aldrich, USA) stirring at a rate of 1000 rpm for 10 minutes to form an emulsion. The 
emulsion was then added to 0.5% PVA stirring at 700 rpm overnight to remove PVA. 
Microparticles were then collected by centrifuging, washed 5 times with distilled water, and 
dried by lyophilization.  
 
In Vitro Controlled Release  
 Microparticles (5 mg) were placed into 1 mL of PBS in a micro centrifuge tube and 
placed on a shaker at 37°C/5% CO2. A sample (0.5 ml) was taken out, measured, and 
replaced every 24 hours. UV/VIS Spectrophotometer (Beckman Coulter, USA) was used to 
measure the drug concentrations at wavelengths of 261 nm (Nutlin-3a) or 254 nm (GCV). 
Standard curve based on Beer’s Law was created to convert absorbance to concentrations 
with molar extinction coefficients determined to be 0.0126 for Nutlin-3a and 0.0612 for 
GCV.  
 
Encapsulation Efficiency  
 PLGA microparticles (5 mg) were dissolved in 2 mL DCM for 3 hours at ambient 
room temperature to measure the encapsulation efficiency of the particles. Concentration of 
drug was measured using UV/VIS Spectrophotometer (Beckman Coulter, USA) at 
wavelengths of 261 nm (Nutlin-3a) or 254 nm (GCV).  
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Scanning Electron Microscopy  
 To examine the surface morphology of the particles, about 0.25 mg of PLGA 
particles containing GCV was mounted onto a PEG and sputter coated with gold/allodium 
alloy to create a layer of conducting material. Particle surface was imaged using a scanning 
electronic microscope (SEM)  (LEO/Zeiss) at 100x and 500x magnifications.  
 
Simulation of Controlled Release  
 Release rate of Nutlin-3a from in vitro controlled release was determined from 
experiments. Known elimination rate from the IC50 studies was then incorporated to calculate 
the actual local concentration of the drug at a given point in time until the local concentration 
remained constant. Different release rates were used to determine the minimal release rate 
needed to sustain IC50 levels in the IA space for an extended period of time.  
 
Statistics 
All data was statistically analyzed in GraphPad Prism Software using unpaired t-test with 
welches correction where *p < 0.05, **p<0.01, ***p<0.001 was considered significant. 
2.3 Results and Discussion  
2.3.1  Part A SC Promotion of Cartilage Degradation 
 
SC Reduces Cartilage Matrix Production and Chondrogenic Differentiation Potential 
of hMSCs in 2D and 3D In Vitro Systems 
MSCs are one of the potential cell types that may influence the regeneration process 
in damaged cartilage either directly through new cartilage tissue formation by a process 
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called chondrogenesis, or secretion of pro-regenerative cytokines [21, 22]. In stress related 
injuries such as OA, the resident MSCs in the joint have functional deficiencies in terms of 
altered chondrogenic differentiation and maintenance of articular cartilage tissue [21]. 
Previous studies have also shown that with age, the processes of differentiation, proliferation, 
and angiogenic potential of MSCs are reduced [1] therefore there may be an association 
between cellular senescence and the functional deficiencies seen in chondrogenic potential of 
stem cell populations in the OA knee joint [1].  
To observe the impact of SCs on the chondrogenic linage potential, hMSCs were 
irradiated to induce senescence through DDR and kept in normal growth culture conditions 
for 10 days to allow full expression of SC phenotype [15] before placing into 2D/3D 
chondrogenic differentiation culture for 3 weeks (Fig. 2.3a). Confirmation of SC phenotype 
development after irradiation and subsequent culture for 10 days is shown through increased 
presence of -galactosides stained in the irradiated hMSCs compared to non-irradiated 
hMSCs (Fig. 2.3b). Irradiated hMSCs and control populations were then put into 3D pellet 
culture in chondrogenic differentiation media for 3 weeks. Confirmation of presence of SCs 
in the irradiated 3D pellet samples was seen by increased p16INK4a antibody stain and up 
regulation of p16INK4a and p21Waf1 gene expression compared to 3D control pellet samples 
(Fig. 2.3c, d).  
Overall, senescent hMSC pellets were markedly reduced in size compared to their 
normal, non-irradiated counterparts indicating decreased proliferative capacity, a 
characteristic seen in stem cell populations in OA (Fig. 2.3c).  Safranin-O staining showed 
predominantly less proteoglycan content in the senescent samples of 2D micromass and 3D 
pellet culture systems (Fig. 2.3c). Control 3D pellet controls also had collagen II staining 
28 
throughout the section whereas the senescent samples did not (Fig. 2.3c). IHC results 
confirmed significant down regulation of collagen II, aggrecan, and SOX-9 gene expression 
(Fig. 2.3d) indicating the role of SCs in hindering production of cartilage extracellular matrix 
by altering chondrogenic differentiation potential of MSC populations.   
On the contrary, Type X collagen, a marker of hypertrophic cartilage, and 
osteocalcin, a noncollagenous marker of bone, stained intensely throughout the senescent 
pellet (Fig. 2.3c). Particularly since a hallmark of late stage OA is thickening of the 
subchondral bone and development of boney osteophytes, the role of senescent MSCs in 
producing bone related factors, even in chondrogenic culture conditions suggests these cells 
may play a critical role in OA and even other cases of dysfunctional endochondral 
ossification after injury. 
During early-stage of OA, repair is initiated by stimulation of cytokines, which 
eventually becomes chronic and leads to synthesis of collagenases and aggrecanases that 
degrade the matrix and lead to expression of markers of endochondral ossification [1]. SCs 
have a SASP that includes secretion of cytokines, and thus might contribute to the changes 
seen in the in the cartilage matrix formation in the chronic state of OA. Gene expression of 
IL-1β and MMP3 were elevated in the senescent 3D pellet compared to the control 3D pellet, 
but was not statically significant (Fig. 2.3d). Previous studies however have shown that 
irradiation induced SC hMSCs have higher levels of a large array of inflammatory mediators 
compared to normal hMSC cells [15]. Secretion of inflammatory mediators may be how SCs 
alter chondrogenic differentiation potential of surrounding stem cell populations while 
reducing cartilage matrix production leading to expression of bone formation factors. 
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Healthy Human Chondrocytes Co-Cultured with Senescent Chondrocytes Results in 
Impaired Cartilage Matrix Production and Increased Senescence in Healthy 
Chondrocytes 
The presence of SCs in the joint may lead to OA and degradation of the cartilage 
tissue. To understand how senescent chondrocytes may impact healthy chondrocytes in the 
joint, a co-culture model was employed in vitro where varying concentrations of human 
primary senescent chondrocytes isolated from an OA cartilage sample were cultured with 
human primary healthy chondrocytes isolated from a healthy cartilage sample for 1 week 
(Fig. 2.4b).  
Primary human chondrocytes were isolated from cartilage tissues from healthy and 
osteoarthritic patients for use within in vitro experiments. In order to assess the amount of SC 
intrinsically present in the samples, SA--Gal staining was performed on cartilage explants 
isolated from a normal cartilage sample and OA cartilage sample. SA--Gal was more 
prominently stained in the OA cartilage explant compared to the healthy cartilage explant 
indicating a higher percentage of SCs (Fig. 2.5). Primary cells were also isolated from a 
healthy cartilage sample and OA cartilage sample to determine if the cell isolation process 
caused spontaneous senescence in the chondrocytes. SA--Gal staining showed that there 
were 7% of SA--Gal positive cells in the healthy population and 44% of SA-β-gal positive 
cells in the OA population (Fig. 2.5), therefore showing a minimal level of spontaneous 
senescence due to cell culture.   
Chondrocytes isolated from an OA cartilage sample are a mixed population of healthy 
and SCs, as shown in Fig. 2.5, and there are currently no specific surface markers for sorting 
live SCs [16]. In order generate a SC enriched populations, the mixed chondrocyte population 
30 
isolated from the OA cartilage was sorted into three populations based on size and auto-
florescence [18] which correlated with the level of senescence determined by SA--gal 
staining (Fig. 2.4a). The resulting sorting populations contained different percentages of SCs 
(Low: 26.3%, Medium: 46.9%, High: 65.6%) (Fig. 2.4a) and were cultured with healthy 
chondrocytes to observe a possible SC dose response.  
Healthy primary chondrocytes exposed to high percentage (65.6%) of SCs showed 
significant increases in p16INK4a mRNA levels and decreases in chondrogenesis as defined by 
proteoglycan Safranin O staining and collagen II gene expression level, as compared to 
control (Fig. 2.4c, d). Elevated expression of p16INK4a is related to increases in MMP3 and 
MMP13, both of which play an integral role in OA pathogenesis [23], showing consistency 
with the up regulation of MMP3 expression in high (65.6%) group (Fig. 2.4d). Also, 
affirming the spread of senescence to healthy chondrocytes from exposure to high percentage 
(65.6%) of SC was an almost two-fold increase in p21Waf1 gene expression compared to 
control (Fig. 2.4d).  
A SC dose response of p16INK4a, p21Waf1, MMP3, and collagen II expression was 
observed with the different percentages of SCs, mimicking the age-related accumulation of 
SCs in OA. This suggests that a larger amount of SCs could cause a more detrimental effect 






Healthy Human Chondrocytes Cultured with SC Conditioned Media Results in 
Impaired Cartilage ECM Production and Increased Senescence through Bystander 
Effect of SASPs  
To further assess the effect of SC SASP on healthy human chondrocytes, cell medium 
conditioned from the various SC population groups (control, low, medium, high) in the co-
culture experiment was collected and added onto a monolayer of healthy human 
chondrocytes in culture for 1 week (Fig. 2.6a). Interestingly, healthy chondrocytes grown in 
high, medium, and low percentages of SCs conditioned medium for 1 week showed down-
regulation of proteoglycan production confirmed by Safranin-O and Alcian blue staining 
while exhibiting an increase of SA-β-gal-positive cells in a SC dose dependent manner (Fig. 
2.6c). Quantitative measure of proteoglycan stains and SA-β-gal-positive cells show 
significance between the control and high SC percentage (65.6%) groups (Fig. 2.6d).  
To determine if senescence can be transmitted to the healthy chondrocytes 
surrounding the senescent secretory cell in non-cell-autonomous fashion, the levels of 36 
secreted proteins were measured using conditioned media from the control and high SC 
percentage (65.5%) groups by a human cytokine antibody array (Fig. 2.6b). It is noteworthy 
that many of factors such as GROα (growth-regulated oncogene α), IL-1α, IL-1β, IL-6, 
ICAM-1 (intercellular adhesion molecule 1), CCL5 (chemokine (C–C motif) ligand 5), and 
MIF (macrophage migration inhibitory factor) have been previously reported to be part of SC 
SASP [24,25]. These findings suggested that senescent chondrocytes could induce a bystander 
effect, spreading senescence to their neighboring healthy chondrocytes through SASP and, 
ultimately, contribute to the decline in their abilities to repair damaged cartilage during OA 
32 
progression. This bystander effect therefore may also contribute to the increase frequency of 
SC present in the knee joint with age [26].  
 
IA SC Injection into Healthy Articular joint in C57BL/6 Mice Leads to Age-Related 
Progression of OA by Symptomatic Pain and Reduced Proteoglycan Production  
 We have seen that SC are capable of impacting cartilage formation in vitro, and it is 
known in osteoarthritic conditions that there is an accumulation of SC in vivo. One question 
that remains however is whether introducing SC in vivo can impact the healthy joint 
environment and thus relate SCs to the development of OA in an age-related model.  
 The irradiation and induction of MEF cells was evaluated in vitro before in vivo 
injection of SCs. MEF cells were isolated from transgenic 3MR mice and irradiated at 10 and 
20 grays to induce SC. Induction of senescence was confirmed by bioluminescent 
measurements that showed that increasing irradiation induces a larger population of SC and 
additionally showed that P3 MEF cells had a higher luminescent signal than P1 luminescent 
cells indicating replicative senescence (Fig. 2.7a). Further confirmation of the dosage effects 
of irradiation was conducted on cell line MEF cells and an increase in irradiation was 
accompanied by an increase in SA-β-gal-positive cells and decrease in cell viability (Fig. 
2.7b).  
To avoid replicative senescence more common in the primary 3MR MEF cells 
irradiated and non-irradiated cell line MEF cells were injected into 6-month old CBL57 mice 
to determine the effect of introducing SC into a healthy joint environment (Fig. 2.8a).  
Functional pain tests were conducted every two weeks and animals were harvested at 8 
weeks for further analysis (Fig. 2.8a).  
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Hot plate pain analysis showed an increase in response time in SC treated animals 
compared to non-senescent cell (NC), saline (vehicle), and wild-type (WT) groups 
paralleling the weight bearing pain analysis that showed a lower % weight put on the injected 
leg over the contralateral leg in the SC treated animals compared to NC, vehicle, and WT 
groups (Fig. 2.8b). Over time, weight bearing and hot plate testing show a gradual increase 
in pain in the SC group compared to other groups as well (Fig. 2.8b). Safranin-O staining on 
the medial femoral and tibial surfaces was greatly reduced in the SC treated group indicating 
loss of proteoglycan content (Fig. 2.8c). Gene expression of injected knee joint showed up 
regulation of p16INK4a, p21Waf1, MMP13, IL-1β and down regulation of collagen II and 
aggrecan in SC treated group compared to other groups (Fig. 2.8d).  
These findings suggest that presence of SC in the intra-articular space can cause 
neighboring cells, perhaps through SASP factors such as MMP13 and IL-1β, to become 
senescent further causing damage to the cartilage matrix by loss of proteoglycans and 
reduction of collagen II production. SC can additionally induce adjacent cells to become 
senescent by contact via gap junction-mediated cell-cell contact and processes involving 
reactive oxygen species [26]. This agrees with results seen from co-culture and bystander 
experiments in vitro and highlights the importance of SASP. 
2.3.2 Part B Clearance of SC Prevents PTOA  
 
Nutlin-3a eliminates SCs in in vitro 3D chondrocyte pellet  
We have seen that accumulation and presence of SCs is related to progression of OA 
through reduction of the regenerative capacity of chondrocytes, limiting cartilage matrix 
production. One potential strategy to treat OA therefore is to eliminate SCs through use of 
34 
senolytics, small molecules that selectively kill SCs. As there are many senolytics, and in 
order to begin this investigation, it was first necessary to screen senolytics with chondrocytes 
in vitro to evaluate potential candidates for OA treatment. 
 Five senolytics at different concentrations were screened in vitro with a 3D pellet 
culture of OA human chondrocytes by measuring SA-β-gal positive cells after treatment 
(Fig. 2.9). 3D Culture was chosen because chondrocytes tend to dedifferentiate upon 
monolayer culture but retain phenotype in high-density aggregate cultures [27, 28]. It is to be 
noted that the structure, molecular weight, and name of many compounds are not reveled for 
intellectual property considerations. Additionally, DMSO represents a control for the drug 
vehicle and UNI-2010002 represents a control for inactive compound.  
From the five compounds, Nutlin-3a was the most efficient at eliminating almost all 
SCs at 14 days by the lack of SA-β-gal positive cells seen in both the gross pellet image and 
section. The UNI-2010006 compounds seem to eliminate all SCs at the highest 
concentration, but actually is most likely toxic due to lack of viable cells seen on the 
sectioned image. Nutlin-3a is a potent molecule that activates the p53 pathway in cancer cells 
and leads to apoptosis, which is the mechanism through which it targets SCs. Nutlin-3a 
provides as a promising compound to further investigate whether elimination of SCs is an 
effective therapeutic strategy for OA in vivo.  
 
Clearance of SCs by GCV treatment prevents the development of the PTOA 
Before determining if Nutlin-3a was an effective senolytic for OA treatment in vivo, it 
was necessary to validate the effect on OA pathology of clearing p16INK4a positive cells to 
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assess if this is a viable treatment strategy. To determine if clearance of SCs is related to the 
progression of OA, GCV was injected IA 2 weeks after ACLT surgery (Fig. 2.10a)  
Decreased luminescence level along with reduced gene expression levels of the 
senescence associated proteins p16INK4a and p21Waf1 confirmed elimination of SCs after GCV 
treatment (Fig. 2.10b, 2.10e). Clearance of SCs by GCV also caused inhibited articular 
cartilage erosion and rescue of proteoglycans, resembling normal tissue with an increase in 
aggrecan and collagen II gene expression in comparison to untreated group (Fig. 2.10c, 
2.10e). OA pathology and SC accumulation was confirmed with expression of inflammatory 
cytokines, IL-1β and MMP13 in untreated group compared to GCV treated group (Fig. 
2.10e). Functional testing of OA-induced pain, that is, weight bearing on the surgical limb 
and hotplate response analysis, revealed ACLT surgery caused mice to favor the contralateral 
leg over the injured leg and have an increase latency period for the injured hind limb to reach 
a pain threshold after placement onto a 55°C platform (Fig. 2.10d). Furthermore, 
administration of GCV caused mice to have a more even weight distribution between both 
hind legs and also decreased the latency period for the pain threshold on hot plate (Fig. 
2.10d).  These results show that clearance of SCs by selective elimination of p16INK4a 
expressing cells restores cartilage integrity while reducing pain and is thus a viable strategy 
for treatment of OA.  
 
SC clearance by treatment with Nutlin-3a prevents the development of PTOA and 
creates a pro-chondrogenic environment 
The p16-3MR transgenic model exhibited accumulation of SCs following ACLT and 
the potential therapeutic effects of eliminating SCs from the joint space therefore use of the 
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ACLT animal model on C57BL/6 mouse was employed to determine the efficacy of IA 
injection of senolytic agent Nutlin-3a for treatment of OA (Fig. 2.11a). Increased cartilage 
formation and proteoglycan content by Safranin-O staining resulted in a lower OARSI score 
for Nutlin-3a treated group and shows evidence for the efficacy of IA injection of Nutlin-3a 
for treatment of OA (Fig. 2.11b). Behavioral testing of OA-induced pain showed Nutlin-3a 
treatment caused mice to favor the contralateral leg over the injured leg significantly less and 
also significantly decreased the latency period for the induced OA hind limb to reach a pain 
threshold compared to ACLT and Sham groups (Fig. 2.11c). Coinciding with these results, 
mRNA expression levels encoding p16INK4a, the SASP factors IL-6, and MMP13 and IL-1β 
were down regulated whereas collagen II was up regulated with Nutlin-3a treatment (Fig. 
2.11d). No significant change in aggrecan mRNA expression was observed, which may be 
due to the fact that one injection may not be the optimal regime for treatment.   
Modulating the number of Nutlin-3a injections could provide a further efficacious 
effect on OA progression. To explore this further, between zero-six injections of Nutlin-3a at 
1mM was injected IA into C57BL/6 mice to observe the effect of multiple pulsatile 
exposures of compound to the articular space. Gene expression data showed that five and six 
injections of Nutlin-3a caused further decrease of senescence-related markers p16INK4a and 
inflammatory cytokines MMP13 and IL-1β while causing increase of collagen II and 
aggrecan gene expression compared to one injection (Fig. 2.12a). Unlike results from single 
injection, five-six injections of Nutlin-3a stimulated proteoglycan production (Fig. 2.12a). 
Behavioral testing results show that there is a reduction in weight placed on contralateral leg 
and decrease in hot plate latency time in groups that received five and six Nutlin-3a 
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injections (Figure 2.12b). Multiple injection results indicate the clinical efficacy of having 
sustained exposure of the joint to Nutlin-3a for an optimized period of time.  
 
Nutlin-3a has short residence time in the joint and initial development of a sustained 
release formation  
We found that multiple injections improved the efficacy of Nutlin-3a treatment in 
comparison to a single injection. To explore this further, the pharmokinetics (PK) of Nutlin-
3a in the articular joint was explored and it was found that the lifetime of Nutlin-3a in the IA 
space is short, and the concentration of the compound falls below the half-maximal inhibitory 
concentration (IC50) of 25μM after only 1.5 hours (Fig. 2.13a). Additionally, 3.3% of the 
dose reaches systemic circulation and never reaches the IC50 systemically. The short time of 
Nutlin-3a in the joint explains why multiple doses were more efficacious than a single dose. 
Short half-life also indicates a potential clinical applicability of a sustained release 
formulation to deliver Nutlin-3a for an extended period of time.  
Preliminary work in this area involved integrating Nutlin-3a into a PLGA 
microparticle formation created by oil in water emulsion and observing the in vitro release of 
the compound for 10 days. Since Nutlin-3a is very hydrophobic, GCV (hydrophilic) was also 
encapsulated in PLGA particles as a control. The surface morphology of the GCV particles 
was smooth and did no have large pores, as seen by the SEM images (Fig. 2.14a). The 
diameter the PLGA microparticles was also measured from different batches and was 
determined to fall within the range of 1-8 micrometers (Fig. 2.14b). Lastly, the encapsulation 
efficiency of the particles was measured and found to be 89.44% for Nutlin-3a and 13.4% for 
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GCV (Fig. 2.14c). This was expected, as GCV is hydrophilic and would require water in oil 
in water emulsion to have better encapsulation rather than oil in water emulsion.  
In vitro release data was collected for a period of 10 days for Nutlin-3a (Fig. 2.13b). 
Since Nutlin-3a is a large molecule, very hydrophobic, and has low aqueous solubility, the 
release from the PLGA microparticles was primarily bulk erosion based and thus very slow. 
Cumulative concentration reached the IC50 after 10 days, but this in vitro set-up does not 
account for the elimination of Nutlin-3a in the environment occurring at the same time and 
therefore does not accurately depict the true concentration that would be in the joint 
environment. In order to incorporate the elimination of Nutlin-3a from the environment, the 
concentration of Nutlin-3a in the joint was simulated by taking into consideration arbitrary 
release rates from the microparticles every hour and subtracting the eliminated amount of 
drug every 1.5 hours from this total amount until a steady concentration was reached  (Fig. 
2.13c).  
It was found that based on the rate of the release of Nutlin-3a from the in vitro study, 
0.157µM/hour, the amount of compound in the knee joint would not be able to reach the IC50 
and therefore would not have therapeutic efficacy. It was determined that minimum rate of 
release of Nutlin-3a from the microparticle, or another type of release formulation, would 
have to be 6.5μM/hour. Possible future work in this area could include a gel-based 
formulation such as a hyaluronic acid gel that would quickly release the drug, using 
crystalized drug formulations, or increasing the drug load of the microparticles. In addition, it 
is to be noted that the actual release in vivo of the formulation may be accelerated compared 
to the in vitro release rate due to the inflammatory environment of the knee that may 
catabolize polymers [29].  
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The efficaciousness of Nutlin-3a treatment on PTOA in old mice  
 Aging is a risk factor for development of OA, and it would be interesting to see if SC 
removal in PTOA injury model in old mice results in a similar disease modification as in 
young mice. Transgenic p16-3MR mice 19-months in age were subject to ACLT and injected 
IA with Nutlin-3a.  
The contralateral leg was also evaluated to learn if SCs and OA were naturally 
occurring with age. Luminescence results show a low level of p16INK4a expressing cells in the 
contralateral leg and safranin-o staining showed minor changes in proteoglycan content 
throughout the tibial plateau compared to a normal young mice resulting in an OARSI score 
of 2 (Fig. 2.15a,b). Pain results for mice that had no surgery however were similar to that of 
young mice (Fig. 2.15c). Together, these results show that old 3MR mice may have age-
related SC accumulation in the IA joint have some cartilage depredation that could attribute 
to mild OA.  
ACLT mice showed increase in luminescence level in addition to cartilage lesions in 
the medial tibial plateau and significant proteoglycan loss resulting in severe OA. In 
comparison Nutlin-3a treated group had a significant reduction in luminescence indicating 
targeting of p16INK4a positive cells, but had only slight improvement in proteoglycan content 
and OARSI scoring (Fig. 2.15a,b). Pain results show slight decrease in favoring the 
contralateral leg in weight bearing measurements and slight decrease in hot plate latency 
period for Nutlin-3a treated group (Fig. 2.15c). Decreased mRNA levels of p16INK4a and 
p21Waf1, the SASP factors IL-6 and MMP13 was observed in Nutlin-3a treated old mice 
compared to ACLT group (Fig. 2.15d). On the contrary, Nutlin-3a treatment did not have 
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significant up regulation of collagen II and aggrecan (Fig. 2.15d) as seen in young mice, 
agreeing with histological results.  
Overall results show that Nutlin-3a may still target and eliminate SC in the IA space, 
but does not result in the same pro-chondrogenic environment as seen in young mice. One 
possible reason for this is that the proliferative and regenerative potential of articular 
chondrocytes declines with age [30]. Age is also effects basal patterns of gene expression in 
joint tissues and the response to surgically induced OA [31].  
 
Nutlin-3a is efficacious in ACLT model in rat and further evaluation of other senolytics 
 Nutlin-3a provides as a promising senolytic for treatment of OA. One consideration 
however, is if the potential therapeutic advantage is just limited to the mouse model. To 
explore this a little bit further, a drug screen of different dosing regimens of Nutlin-3a and 
another senolytic compound, #911, was performed in a rat model.  
The OA-induced pain was measured on the basis of weight distribution between 
surgery operated and contralateral legs and von Frey test that measures pain response to 
pressure contact. It was found that groups 3, 4, 11 had the most balanced and stable posture 
indicating less pain (Fig. 2.16). Group 3, 6, 7, 11, 12 showed increase in withdrawal 
threshold, showing decrease in mechanical sensitivity/pain (Fig. 2.16). Overall mRNA gene 
expression data shows that group 3 and 11 are the best treatments compared to all other 
compounds and regimes based on down regulation of p16INK4a, MMP13, IL-6, IL-1β and up 
regulation of collagen and aggrecan (Fig. 2.17).  These results cumulatively show that 
Nutlin-3a is efficacious in the rat model in addition to the mouse model, and that compound 
#911 may have some efficacy as well. Efficacy of compound #911 however was not 
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predicted by in vitro 3D chondrogenic pellet drug screen (Fig. 2.9) indicating that the drug 
may have a mechanism of action that is dependent on more complex biological processes 
then can not be mimicked in vitro.  
 
2.4  Conclusion  
2.4.1 Part A SC Promotion of Cartilage Degradation 
The functional deficiencies in stem cell populations in the osteoarthritic knee joint 
can be attributed partially to senescence of mesenchyme stem cell populations causing 
decreased proliferative and chondrogenic potential by growth arrest and secretion of pro 
inflammatory cytokines. This negatively affects cartilage matrix regeneration through 
reduced production of collagen II and aggrecan, which could contribute to hypertrophy of the 
subchondral bone. In addition, indirect contact of healthy cells and SCs through co-culture 
model and bystander effect shows that the SASP plays an important role in how SCs affect 
neighboring healthy cells and can cause them to become senescence along with hindering 
ability to produce cartilage matrix contributing to the OA pathology. The presence of a larger 
portion of SCs causes a more detrimental impact and further progresses the disease of the 
joint. Additionally, senescence may also be related to the onset of OA as introducing SCs 
into the joint for a sustained time resulted in cartilage degradation, pain, and further 
accumulation of SCs in vivo indicating early-state OA. 
2.4.2  Part B Clearance of SC Prevents Development of PTOA 
In vitro drug screen of senolytic compounds showed that Nutlin-3a was a viable 
compound for the clearance of SCs. Nutlin-3a is a potent molecule that activates the p53 
pathway in cancer cells and leads to apoptosis. Transgenic p16-3MR mouse model of PTOA 
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induced by ACLT was then used to confirm the accumulation of SCs in the knee joint and 
that selectively killing p16INK4a expressing cells reduced the progression of OA. The effect of 
Nutlin-3a was then evaluated in vivo and was found to mitigate symptomatic pain while 
modifying disease through generation of a pro-chondrogenic environment promoting 
cartilage matrix production and reducing inflammatory and SASP factors. Pharmokinetics 
showed that Nutlin-3a remains in the joint for a short period of time, and that multiple 
injections improve the efficacy of the treatment proposing the need for a sustained release 
formulation. Nutlin-3a was also shown to an effective treatment in rat model of PTOA, 
where it was shown that there are other senolytic compounds such as #911 may also be 
effective in the context of OA. Although Nutlin-3a produced positive results in young mice, 
it proved not as effective of a treatment in old mice, most likely due to reduced regenerative 
capacity of chondrocytes with age.  
 
2.5  Future Directions  
2.5.1 Part A SC Promotion of Cartilage Degradation 
Future work to elucidate how SCs affect healthy cells in vitro can include a number 
of different experiments. The effect of direct contact of SCs and healthy cells would be 
interesting to evaluate if this further reduces chondrogenic characteristics of chondrocytes 
than just in direct contact. Additionally, a more in depth analysis of the SASP can be evaluate 
in the future to determine which particular factors are related to the contribution of age-
related OA and PTOA. Lastly, the injection of SCs into the joint can be conducted again with 
tagged cells so that it can be determined if the cells are residing in the joint or migrating out 
and with a longer time point and multiple cell injections. One consideration in the 
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experiments performed is that artificially induced senescence, in this case through irradiation, 
may not be the same as natural cellular senescence. Previous studies have shown that the 
major SASP components between irradiated human MSCs replicative induced senescence 
human MSCs are conserved [14] but this should also be explored within context of OA and 
chondrocytes  
2.5.2 Part B Clearance of SC Prevents Development of PTOA 
Since efficacy of multiple Nutlin-3a treatments was observed, there is a need to 
develop a sustained release formulation for delivery of Nutlin-3a for an optimized timeline at 
the IC50 level. Optimized regime for treatment of older populations and age-related OA and 
treatment using other senolytics that could also be explored more in the future. This work 
also alluded to the importance of immune related factors such as pro-inflammatory cytokines 
and MMPs in disease pathology. Future work can include determination of the types of 
immune cells present in the IA joint during the progression of OA and in the treatment phase.  
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Figure 2.1 Senescence-inducing stimuli and main effector pathways [2] 
Different types of internal and external stresses can lead to induction activation of p16INK4a 
















Figure 2.2 Accumulation of SC in the Knee Joint of PTOA 3MR-p16 Mouse Model 
p16-3MR mice either underwent sham surgery or anterior cruciate ligament transection 
(ACLT). (a) p16-3MR transgenic mice contain a bacterial artificial chromosome with the 
p16INK4a promoter, luciferin and RFP imaging modalities, and herpes simplex virus 
thymidine kinase (HSV-TK) for selectively killing. (b) Representative luminescence images 
of sham and ACLT mice at 28 days (Left) and quantification of the luminescence at the 
indicated time (days) after ACLT surgery (Right). (c) Quantification of mRNA expression 







Figure 2.3 SCs impairs chondrogenic potential and reduces ECM production of human 
mesenchymal stem cells in 2D and 3D culture 
(a) Timeline of inducing SCs and Culture in 2D and 3D systems (b) Confirmation of SCs 
induced by X-Ray Irradiation by SA-β-gal staining. (c) Immunohistochemical (p16INK4a, 
Type II and Type X collagen (Col II and Col X), and osteocalcin (OCN)) and Safranin-O 
staining (2D and 3D Systems) of non-senescent or senescent hMSCs induced by irradiation. 
(d) Quantification of mRNA expression for p16 INK4a, p21Waf1, IL-1β, MMP3, Col II, 





Figure 2.4 SC chondrocytes co-cultured with healthy human chondrocytes cause 
impaired cartilage ECM production and increased senescence of healthy chondrocyte 
population 
(a) Gating strategy to sort senescent human OA chondrocytes from mixed non-senescent 
chondrocytes based on size and auto-fluorescent age pigment by flow cytometry (left) and 
representative SA-β-gal images of sorted cells from each gate used for co-culturing with 
human healthy chondrocytes (right). (b) Schematic of experiment for c-d Co-cultures where 
sorted High (65.6%), Med (46.9%), and Low (26.3%) SCs are placed within the insert and 
cultured in presence of a monolayer of healthy chondrocytes for 7 days. Control cultures 
contained only healthy chondrocytes. (c) Safranin-O staining of healthy chondrocytes that 
were co-cultured with different percentages of SCs. (d) quantification of mRNA expression 







Figure 2.5 Presence of SA-β-gal-positive SCs in human healthy vs. osteoarthritic 
articular cartilage 
SA-β-gal-positive SCs were observed throughout the depth of osteoarthritic cartilage but 
decreased SA-β-gal staining was present in healthy cartilage. A range of 7-15% SA-β-gal-
positive SCs were observed in primary chondrocytes isolated from healthy cartilage (Passage 
0) and 41–50% SA-β-gal-positive SCs were detected in primary chondrocytes isolated from 






Figure 2.6 Healthy human chondrocytes cultured with SC conditioned media results in 
impaired cartilage ECM production and increased senescence through bystander effect 
of SASPs 
(a) Schematic of experiment for b-d. Healthy human chondrocytes were cultured for 1 week 
with senescent cell conditioned medium from the co-culture experiment shown in Figure 2.4. 
(b) Conditioned media from healthy chondrocytes (Control) or High SCs was analyzed by 
human cytokine antibody arrays. (c) Induction of senescent and cartilage ECM production in 
healthy chondrocytes was measures by SA-β-gal, Safranin-O, and Alcian blue staining. (d) 






Figure 2.7 Confirmation of SC induced by irradiation in primary 3MR MEF cells and 
in AATC MEF cell line 
(a) Confirmation of induction of SC by bioluminescent images of p16-3MR MEF Cells from 
non-irradiated passage 1 (P1), non-irradiated passage 3 (P3), irradiated P3 (10 Grays), and 
irradiated P3 (20 Grays) (left) and quantification of bioluminescence (right). (b) 
Confirmation of induction of SCs by SA-β-Gal staining (left) with quantification of SA-β-
Gal positive cells at different irradiation dosages (middle) and quantification of cell viability 







Figure 2.8 IA injection of SCs into healthy articular joint in C57BL/6 mice leads to age-
related progression of OA by reduced proteoglycan production and symptomatic pain 
(a) Timeline of experiment. Mice were injected with non-SC, SCs, or saline and pain was 
measured every 2 weeks. Mice were sacrificed for further analysis at 8 weeks. (b) The 
percentage of weight placed on the operated limb versus contralateral control and response 
time of mice after placement onto a 55°C hotplate on 8 weeks after SC Injection (top) and 
every 2 weeks for the duration of the experiment (bottom). (c) Representative images 
safranin O/methyl green from C57BL/6 mice to evaluate the pathological changes 8 weeks 
after SC Injection, proteoglycan (red) and bone (green) and OARSI scores. (Wild-type (WT), 
n=3; Vehicle-treated (Veh), n=3; senescent cell (SC) injection, n=3; non-SC (NC) injection, 
n=3). (d) Quantification of mRNA expression for p16INK4a, p21Waf1, MMP13, IL-1β, Col II 





Figure 2.9 Nutlin-3a eliminates SCs in in vitro 3D chondrocyte pellet 
3D cultured pellets of human OA chondrocytes were treated with different concentrations of 
senolytic compounds for 4 days and stained with SA-β-gal (Gross images (left) and sectioned 





Figure 2.10 Clearance SCs by GCV treatment prevents the development of PTOA 
(a) Schematic of experiment for c-f. p16-3MR mice undergoing the ACLT of one hind limb 
to induce OA was injected IA with vehicle (Veh) or gancyclovir (GCV, 2 mM) for 2 weeks. 
(b) Representative luminescence images of ACLT mice after vehicle or GCV treatment 
(Left) and quantification of the luminescence at the indicated time (days) after ACLT surgery 
(Right). (c) Safranin O/methyl green from p16-3MR mice to evaluate the pathological 
changes 4 weeks after ACLT, proteoglycan (red) and bone (green) (Left) and OARSI Scoring 
(Right). (d) The percentage of weight placed on the operated limb versus contralateral 
control (Left) and response time of mice after placement onto a 55°C hotplate (Right) on day 
28 after ACLT surgery. (f) Quantification of mRNA expression for p16INK4a, p21Waf1, 
MMP13, IL-1β, Col II and Aggrecan in joints from no surgery, sham, and ACLT mice 
treated as indicated (n=5 mice per group).  
54 
 
Figure 2.11 Senescence clearance by treatment with Nutlin-3a prevents the 
development of the post-traumatic OA and creates a pro-chondrogenic environment 
(a) Schematic of experiment for b-d. Wildtype C57BL/6 mice underwent the anterior ACLT 
of one rear limb to induce OA in the joint of that limb and were injected IA with vehicle 
(Veh) or Nutlin 3a (NUT3a, 1mM) post-surgery for 2 weeks. (b) Representative images 
safranin O/methyl green and OARSI scores from C57BL/6 mice to evaluate the pathological 
changes 4 weeks after ACLT (No surgery, n=6; Sham surgery, n=5; Vehicle-treated, n=10; 
NUT3a-treated, n=12). (c) The percentage of weight placed on the operated limb versus 
contralateral control and response time of mice after placement onto a 55°C platform in 
hotplate analysis on day 28 after ACLT surgery. (d) Quantification of mRNA expression for 





Figure 2.12 Efficaciousness of a different number of Nutlin-3a injections on OA 
progression 
C57BL/6 mice that underwent the ACLT of one rear limb to induce OA in the joint of that 
limb were treated with vehicle (Veh) or a different number of Nutlin-3a intra-articular 
injections (1 mM, 1 to 6 injections). (a) Quantification of mRNA expression for p16INK4a, 
MMP13, IL-1β, Col II and Aggrecan in joints 28 days after ACLT, n=2 for each group. Data 
are averages ± SD.  (b) The percentage of weight placed on the operated limb versus 
contralateral control and response time of mice after placement onto a 55°C platform in 






Figure 2.13 Nutlin-3a has Short Residence Time in the Joint and Initial Development of 
a Sustained Release Formation 
(a) Local and blood Pharmacokinetics (PK) of Nutlin-3a after intra-articular injection. 
C57BL/6 mice were injected IA with 1mM Nutlin-3a (5.8 µg/10 µl per knee) (N=2 mice per 
time point). Initial dose of Nutlin-3a is below IC50 after 1.5 hour in the joint after IA 
injection. 1/30th of initial dose gets into systemic circulation and IC50 never reached in 
circulation. (b) In vitro release of Nutlin-3a from PLGA microparticles for 10 days to 
determine release rate (Top) and encapsulation efficiency of compounds (Bottom) (c) 
Simulation of controlled release from PLGA microparticle formulation of Nutlin-3a at 
different rates and predicted concentration in the joint compared to the half maximal 







Figure 2.14 Characterization of PLGA Drug Loaded Particles  
(a) Scanning electron microscope (SEM) image of GCV loaded particles taken at 100x 
magnification (left) and 500x magnification (right) (b) Encapsulation efficiency of the drug 
load in GCV particle formulation and Nutlin-3a particle formation synthesized by oil in 
water emersion (c) Diameter of a volume of three different samples of PLGA particles 










Figure 2.15 Efficaciousness of Nutlin-3a treatment on post-traumatic OA in old mice 
19-month old p16-3MR that underwent the ACLT of one rear limb treated with vehicle (Veh) 
or Nutlin-3a (NUT3a, 1 mM) once every two days over 2 weeks starting 3 weeks post-
surgery. (a) Representative whole body luminescent images of vehicle (Veh) or 1 mM of 
Nutlin-3a-treated p16–3MR mice luminescence images after 28 days following IA injection 
(Left) and quantification of luminescence, n=5 for each group (Right). (b) Representative 
images of Safranin O/methyl green staining of sagittal sections of the medial compartment. 
Black arrow indicates areas with the loss of proteoglycan at 28 days after ACLT (Left) and 
OARSI score (Right). (c) The percentage of weight placed on the operated limb versus 
contralateral control and response time of mice after placement onto a 55°C platform in 
hotplate analysis on day 28 after ACLT (n=6 for no surgery group; n=8 for vehicle-treated 
and Nutlin-3a treated group) (d) Quantification of mRNA expression for p16INK4a, p21Waf1, 






Figure 2.16 Efficacy of clearance has SCs by Nutlin-3a and #911 in treating pain in 
PTOA rat model 
Rats that underwent the ACLT of one rear limb treated with vehicle (Veh) or Nutlin-3a or 
#911 at a specified regimen once every two days over 2 weeks starting 3 weeks post-surgery. 
OA-induced pain on the basis of weight distribution between OA surgery operated and 
unoperated contralateral legs was measured (Left) as well as Von Frey test for pain based on 
tactile sensitivity to touch/pressure by applying Von Frey monofilaments were applied to the 
plantar hind paw with a series of filaments that ranged in stiffness from 10 to 60. Baseline 





Figure 2.17 Efficacy of clearance of SCs by Nutlin-3a and #911 in treating PTOA rat 
model 
Rats that underwent the ACLT of one rear limb treated with vehicle (Veh) or Nutlin-3a or 
#911 at a specified regimen once every two days over 2 weeks starting 3 weeks post-surgery. 
Quantification of mRNA expression for p16INK4a, p21Waf1, IL-6, MMP13, Col II, and 
Aggrecan in joints on day 28 after ACLT, n=2 for each group.  
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Chapter 3. Intra-articular Injection of Matristem Reduces 
Development of Post-Traumatic Osteoarthritis 
 
3.1  Introduction 
3.1.1 Extracellular Matrix  
The extracellular matrix (ECM) consists of tissue-specific structural and functional 
molecules that are secreted by resident cells of the local tissue environment [1] and is an 
initiator of biochemical and biomechanical cues for homeostasis, differentiation, and tissue 
morphogenesis [2]. Cellular products modify ECM and reciprocally the ECM signals to the 
cell through integrins, growth factors, and cytokines to cause metabolic and secretory 
changes [3]. The primary components of ECM include hydrophilic proteoglycans and 
structural fibrous proteins [2]. Collagen, the most abundant structural protein regulates cell 
adhesion and migration, directs tissue development, and imparts tensile strength [2]. Other 
structural proteins such as fibronectin and elastin facilitate cellular attachment and contribute 
to elasticity, respectively [4]. Proteoglycans are composed of glycosaminoglycans (GAG) that 
are attached to a polypeptide link protein and can also regulate activates of secreted proteins 
[4]. The highly viscoelastic properties of proteoglycans allow them to impart high 
compressive strength to tissues such as cartilage. Macromolecular components of the ECM 
are secreted primarily by fibroblasts and then degraded by MMPs [4].  
3.1.2 ECM as a Biomaterial  
Scaffolds composed of ECM have been shown to aid in tissue remodeling in 
preclinical animal and human clinical studies [1]. For example, dehydrated human 
amnion/chorion membrane (dHACM) has previously been studied to modulate the 
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development of OA and found to prevent cartilage lesions and partial erosions in addition to 
preventing proteoglycan loss [5]. ECM is a viable regenerative therapy for a wide-range of 
applications due to the presence of bioactive molecules that can drive tissue regeneration and 
homeostasis [3]. Natural materials such as ECM also are advantageous over synthetic 
materials in degradability and biocompatibility [3]. The functional outcome of ECM is 
dependent upon the ability to modulate the immune response, surface topology, 
microenvironmental cues, and growth factor retention [3].  
MatriStem® is a commercially available ECM material made from urinary bladder 
matrix (UBM), one of the most widely studied types of ECM scaffold materials [1]. After 
decellularization process, the ECM contains much biochemical diversity and maintains 
mechanical integrity [6]. UBM specifically contains collagen VII, V, II, IV, V, VI [1] and has a 
luminal surface with a smooth basement membrane and an underlying surface with a mesh of 
connective tissue [7]. Presence of the basement membrane complex has been shown to help 
regulate cell growth, differentiation, and migration during tissue reconstruction [7]. Studies of 
macrophage polarization have also shown presence of UBM coating on polypropylene mesh 
induces a higher M2/M1 in vitro and in vivo, thus leading to more constructive tissue 
remodeling [8].  
UBM has been applied clinically for treatment in open wounds allowing for skin 
grafting and closure [9] and in volumetric muscle loss applications resulting in promotion of 
muscle repair [10].  The immunomodulatory and physicochemical properties of UBM make it 
an attractive therapeutic for OA as well, as OA—previously regarded as a predominantly 
biomechanical disease [1]. The ability of UBM to have a therapeutic effect on OA was tested 
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by measuring inflammatory cytokine gene expression in primary chondrocytes and injecting 
micronized UBM into a PTOA mouse model to evaluate pathological changes.  
3.2  Materials and Methods  
 
Human Chondrocyte Isolation and Cell Culture  
Human chondrocytes were isolated from OA cartilage sample as described in Section 
2.2.1. Chondrocytes were plated in a 6-well plate (~250,000 cells/well) in chondrocyte media 
and incubated for 4 hours at 37°C/5%CO2 before adding IL-1 (10ng/ml) to the media to 
keep the chondrocytes in inflammatory state. Cells were incubated for 16-18 hours at 
37°C/5%CO2 before addition of UBM and then incubated for 24 hours until cell isolation for 
PCR.  
 
Alamar Blue Assay 
Human OA chondrocytes were plated at a density of 10,000 cells/well in a 96-well 
plate and incubated at 37ºC until attachment occurred, after which 10ng/ml of IL-1 and 
varying concentrations of UBM were added to the media and allowed to incubate for 24 
hours. Alamar Blue® reagent (10 µL; ThermoFisher Scientific, USA) was added directly into 
each well and the plate was incubated at 37ºC for 3 hours protected from light. Absorbance 
was measured using a microplate reader every hour for 3 hours at a wavelength of 570 nm. 
Data were normalized to readings at 600 nm. These measurements were used to calculate 





Surgically Induced OA Mouse Model  
 ACLT was performed on 10-week old C57BL/6 mice as previously described in 
Section 2.2.1.  
 
IA Injection  
Two weeks post ACLT, a single 10µL IA injection of PBS (control) or UBM (50 
mg/mL in PBS; pH 7.2; ACell, USA) was administered to the mice in the operated knee 
using a 30-guage needle (n=13 mice at 4-week time point, n=8 mice at 8-week time point).  
 
Histological evaluation:  
 Histological evaluation was performed as previously described in Section 2.2.1.  
 
RT-PCR analysis:  
 RT-PCR analysis was performed as previously described in Section 2.2.1. Primers 
are listed in Table 1 and Table 2.  
Weight Bearing Assessment:  
 Weight bearing assessment was performed as previously described in Section 2.2.1.  
 
Hot Plate Assessment:  





Statistical analysis was conducted using one-way ANOVA test with Holm-Sidak 
multiple comparison in GraphPad Prism Software. P < 0.05 was considered significant. 
 
3.3  Results and Discussion  
 
UBM decreases inflammatory markers in human primary OA chondrocytes  
In OA, the presence of inflammatory cytokines provokes immune cell infiltration and 
helps lead to disease pathology [3]. To determine the ability of UBM to have 
immunomodulatory capabilities, UMB was added at different concentrations onto primary 
human OA chondrocytes for 1 day then quantitative PCR was performed on inflammatory 
and catabolic markers. MMP13, a matrix-degrading enzyme involved in the progression of 
OA [11], as found to be significantly down regulated in the highest dose of UBM of 1g/mL 
(Fig. 3.1a). Expression of TNF-alpha and IL-1β are also associated with OA and activate the 
NF-kβ signaling pathway [12]. The mRNA gene expression levels of TNF-alpha, IL-1β, and 
NF-κβ all showed a dose dependent decrease with increase in UBM concentration, although 
this was not significant (Fig. 3.1a). Gene expression of IL-6, another cytokine up regulated in 
OA [13], showed a non-significant dose dependent decrease with increase of UBM 
concentration (Fig. 3.1a). Trends of this data show that UBM could potentially help to treat 
OA by decreasing pro-inflammatory factors in the joint space that lead to cartilage 
degradation. It is possible that the decline in IL-6 and IL-1β can be attributed to the shift in 
macrophage towards a more regenerative environment [3] for the chondrocytes. The presence 
of inflammatory cytokines provokes immune cell infiltration and cause phenotypic changes 
in surrounding cells causing chronic inflammation that leads to disease pathology [3]. 
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Cytotoxicity of UBM used was then tested using an alamar blue assay (Fig. 3.1b). The 
Alamar Blue assay showed that the cell viability did not change significantly compared to the 
control of no addition no UBM at any of the UBM concentrations.  
It was observed during cell culture that the UBM particles naturally resided around 
the cells in the culture dish. To further investigate the interaction between the material and 
the cells, confocal imaging was performed 24 hours after UBM addition to the chondrocytes. 
Confocal imaging showed that UBM particles were not taken up by the cells (Fig. 3.1c), 
most likely due to the micron size of the particles, but were almost completely engulfed by 
the cell evidencing the strong interaction of these particles with cells.  
 
UBM injection treated PTOA mice show reduced disease progression by histological 
analysis  
 In order to test the efficacy of UBM in context of OA, an ACLT mouse model was 
employed. ACLT was induced in mice and UBM or saline was injected in mice 2 weeks post 
surgery after which end point evaluation was conducted at 4 weeks and 8 weeks (Fig 3.2a). 
Proteoglycan content is essential in maintaining cartilage integrity as it contributes to its 
viscoelastic properties [14]. Collagen II is also an important component of the cartilage matrix 
as it imparts the ability to withstand tensile forces [15]. At both 4 week and 8 week time 
points, ACLT mice that were treated with saline exhibited proteoglycan loss (Fig. 3.2c; 
arrows) and cartilage lesions (Fig. 3.2c; stars) on the tibial articular cartilage. UBM treated 
mice had less severe cartilage lesions and more proteoglycan staining compared to the saline 
control at 4 weeks (Fig. 3.2c) and had a significantly lower OARSI score (Fig. 3.2b). The 
UBM treated group also had a significantly lower OARSI score at 8 weeks than the 8-week 
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saline treated control (Fig. 3.2b), but less proteoglycan content compared to the 4-week 
UBM treatment group (Fig. 3.2c).  
Cytokines such as IL-1 and TNF-alpha are produced by synoviocytes in OA and 
cause MMP gene expression that lead to the breakdown of cartilage macromolecules [16]. In 
addition, these factors also inhibit the ability of chondrocytes to produce more cartilage 
matrix [16] and thus can contribute to the proteoglycan loss seen in the histology in the ACLT 
saline injection group. The difference between the UBM treated group at 4 weeks and 8 
weeks could be attributed possible degraded of UBM and use by cells point by the MMPs 
present in the IA space by the 8-week time [4], and therefore the regenerative nature of the 
joint is unable to be maintained and returns to a more chronic state. 
 
UBM injection treated PTOA mice show reduced inflammatory marker expression and 
increased cartilage matrix production 
 In vitro results provided a basis for observing the ability of UBM to modulate 
immune related factors. To explore this further, the gene expression of inflammatory and 
catabolic markers along with cartilage matrix factors was analyzed in the PTOA mouse 
model at the 4-week time point. Injection of UBM caused a significant down regulation of 
inflammatory markers IL-6 and IL-1β and degrading enzyme MMP13 and up regulation of 
anti-inflammatory markers IL-4 and IL-10 compared to saline injected mice (Fig. 3.3). 
Additionally, UBM injections also caused a significant increase in expression of cartilage 
ECM components collagen II and aggrecan compared to saline injected mice (Fig. 3.3). 
 In OA, the increases in inflammatory cytokines such as IL-6 and IL-1β are known to 
decrease aggrecan and collagen content in cartilage [17], consistent with the gene expression 
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data. The increase in anti-inflammatory factors in gene expression data with UBM treatment 
poses several beneficial effects. IL-4 has chondroprotective effects and inhibits degradation 
of proteoglycans by inhibiting secretion of MMPs while IL-10 stimulates collagen II and 
proteoglycan production, inhibits chondrocyte apoptosis and is involved in chondrocyte 
proliferation and differentiation [17]. Based on gene expression results, it is proposed that the 
UBM is facilitating modulate the immune related factors in the joint environment in a way to 
allows chondrocytes to rebuild tissue more efficiently. This many be why the increased 
proteoglycan content in the UBM treated groups at 4 and 8 weeks in the histology is 
observed.  
 
UBM treatment in mice showed reduced OA-related pain 
 In addition to looking at the disease modifying ability of UBM injections, 
symptomatic pain was measured at 4 weeks and 8 weeks using functional pain testing. UBM 
injections significantly reduced the latency period on hot plate compared to ACLT saline 
injected mice at both 4 and 8 weeks (Fig 3.4a). The weight placed on the surgical leg over 
the contralateral leg at 4 weeks was significantly more evenly distributed in UBM injected 
mice compared to ACLT saline injected mice, which had a preference towards the 
contralateral un-operated leg (Fig 3.4b). These results correlated with the histological results 
(Fig. 3.4) and show that treatment of UBM can help relieve pain. On the other hand, the 
weight-bearing test did not show a significant different between the saline treated and UBM 
treated group at 8 weeks (Fig 3.4b).  
 Since cartilage is aneural, pain associated with OA is attributed to local changes in 
the subchondral bone, periosteium, synovium, joint capsule, and ligaments [18]. Pain can also 
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be associated with OA due to accompaniment of cytokine and substance P release, which can 
make secondary contributions to joint inflammation and pathology [18]. Therefore, the 
histological evidence and pain testing together show the reduction in OA progression with 
UBM injections at 4 weeks and 8 weeks.  
3.4  Conclusion  
 
UBM supports tissue formation rather than forming inferior and less functional scar 
tissue as would naturally occur in post-traumatic injury. Addition of UBM onto chondrocytes 
in vitro showed that UBM lowers levels of inflammatory cytokines and MMPs therefore 
potentially lowering the number of M1 macrophage phenotypes. In vivo injection of UBM in 
PTOA model furthermore showed the immune modulatory capacity of UBM by reduction in 
pro-inflammatory cytokines and increase in anti-inflammatory mediators resulting in 
increases in collagen and aggrecan. In vivo UBM injections additionally encouraged the 
development of proteoglycans both short-term at 4 weeks and long-term at 8 weeks, which 
correlated with reduced symptomatic pain. Particulate UBM has regenerative capacities 
when injected IA into OA knee joint and promotes generation of cartilage tissue matrix 
potentially through modulation of immune related cytokines and factors.   
3.5 Future Directions  
 
Future in vitro work can include doing a macrophage polarization assay to determine if 
UBM causes higher ratio of M2 to M1 macrophages therefore promoting tissue regeneration. 
Additionally, it would be interesting to see if chondrocytes cultured in UBM causes up 
regulation of collagen II and proteoglycans like aggrecan in a more long-term in vitro study. 
In addition, it was observed that there was a rescue of proteoglycan content and cartilage 
lesions at 4-weeks and 8-weeks with UBM injection, but the 8-week animals had a higher 
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OARSI score than the 4-week animals. To evaluate this further, a 12-week time point could 
be done to look at long-term therapeutic effects to assess if the benefit of UBM injections is 
temporal in nature. Multiple injection of UBM (weekly) would also be interested to look at to 
see if it increases therapeutic potential long-term.  
 
3.6 Figures  
 
Figure 3.1 UBM decreased inflammatory markers in human primary OA chondrocytes   
(a) Quantification of mRNA expression for MMP13, ADAMTS5, NF-κβ, TNF-alpha IL-6, 
IL-1β in chondrocytes incubated with Matristem (n=3 per group). (b) Alamar Blue 
Cytotoxicity test for varying concentrations of UMB. (c) Confocal imaging of 1ug/ml UBM 
(left) and 100ug/ml UBM (right) 24 hours after addition into cell culture medium. Red=cell 





Figure 3.2 UBM treated mice show reduced OA progression by histological analysis 
(a) Experimental Schematic of Treatment. C57BL/6 mice undergoing the ACLT of one hind 
limb to induce OA was injected intra-articular with vehicle (Veh) or 50 mg/ml UBM (10μm-
20μm particle size) 2 weeks post-surgery and scarified at 4-week and 8-week time points. (b) 
OARSI scores from the medial tibial plateau of each animal. (c) Representative images from 

















Figure 3.3 UBM treatment Increases Cartilage Matrix and Anti-Inflammatory Genes 
and Decreases Inflammatory Genes  
Mice that underwent the ACLT of one rear limb treated with saline or UBM. Quantification 
of mRNA expression for cartilage matrix genes (aggrecan, collagen II, MMP13), 
inflammatory genes (IL-6, IL-1β) and anti-inflammatory genes (IL-4, IL-10) in joints on day 






Figure 3.4 UBM treated mice show reduction in OA-related pain 
(a) Response time of mice after placement onto a 55°C hotplate 4 weeks and 8 weeks after 
ACLT surgery for all treatment groups (b) The percentage of weight placed on the operated 
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Chapter 4. Hyaluronic Acid Binding Peptide-Polymer System for 
Treatment of Osteoarthritis 
 
 
4.1 Introduction  
 
4.1.1 Synovial Fluid Lubrication  
The healthy diarthrotic joint contains a plasma dialysate termed synovial fluid (SF) 
that is secreted by the synovium to allow for lubrication and passage of nutrients to the 
cartilage [1]. SF provides boundary film lubrication by the surface interactions of molecules 
with the articular cartilage that bear load [2] as well as fluid film lubrication where the vicious 
pressurized fluid between surfaces bears the load [3]. Components of the SF include 
proteoglycan 4 (lubricin), surface-active phospholipids, and hyaluronic acid (HA) [4] all of 
which synergistically work together to provide boundary layer lubrication [5]. The focus on 
the current studies will be on lubrication by HA.  
4.1.2 Hyaluronic Acid in the Healthy Joint  
HA is a negatively charged [1] linear polysaccharide chain composed of repeating 
disaccharide units of N-acetyl-glucosamine and glucuronic acid [6] and is the backbone to 
many proteoglycan complexes [7] such as aggrecan. Given the high molecular weight, HA is 
responsible for the viscosity of SF and has viscoelastic properties that allow it to serve as a 
major lubricant to the articulating joint surfaces [7] by allowing surfaces to glide past one 
another during slow movements and shock absorb during fast movements [6]. Hydration 
lubrication effect of HA may be due to complex with phosphocholine (PC) groups, present in 
articular cartilage and the surrounding SF [5]. PC headgroups coat surface-anchored HA 
creating charged hydration layers that can support high pressures and can be sheared with 
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less frictional dissipation resulting in low friction between surfaces [5]. HA/PC complexes that 
are removed by friction are then replenished by HA and PC molecules, produced by 
chondrocytes and synoviocytes, which permeates the cartilage and synovial cavity [5]. HA 
may attach to the cartilage surface via entanglements of the linear polysaccharide chain with 
collagen or another microfibrillar network in the superficial zone [5]. In addition, 
proteoglycans are retained and anchored to the cartilage surface via HA molecules binding to 
the CD44 receptor on chondrocytes that also helps facilitate chondrocyte proliferation and 
functionality [8]. HA also resides in deeper spaces among collagen fibrils and sulfated 
proteoglycans and thus protects the cartilage by preventing invasion of inflammatory cells 
into the joint space [8]. 
4.1.3 Hyaluronic Acid in the Diseased Joint  
The lubricating capacity of SF in the osteoarthritic knee joint is compromised due to 
structural and compositional changes that lead to increased friction, which causes cartilage 
degradation and abnormal joint movement [9]. Increased levels of pro-inflammatory cytokines 
such as IL-1 and TNF-alpha, aggrecanases, MMPs, and free radicals disrupt the synthesis of 
HA [10,8]. Viscosity of SF is also significantly reduced due to proteinases enzymatically 
cleaving high molecular weight HA into low molecular weight fragments, which are pro-
inflammatory [10,8]. Additionally, OA knee joints have reduced lack of binding of HA onto 
the CD44 receptor, which is correlated with proteoglycan loss on of the cartilage surface [8]. 
Disruption in the functionality of HA lubrication in the OA joint leads to articular cartilage 
wear and accelerates disease progression [10].  
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4.1.4 HA Injection as a Treatment  
A well-known treatment that has been used clinically for OA is viscosupplementation 
in the form of IA injections of hyaluronic acid (HA). These are intended to reduce pain, 
improve function, and possibly have disease-modifying activity [11]. It has been shown that 
exogenous HA may promote the production of newly synthesized HA [8]. Cross-linked HA 
has been developed and used clinically for superior rheological properties, increase retention 
time in the IA space, and more resistance to free radical degradation [7]. One primary 
drawback of an HA injection is that it has a short residence time due to degradation by native 
enzymes [11], lasting about 17 hours for linear HA and 9 days for cross-linked HA [9]. 
Synvisc®, one commercially available viscosupplement, also does not sufficiently provide 
sufficient lubrication, as evidenced by its coefficient of friction of 0.119 in contrast to human 
synovial fluid, which has a coefficient of friction in the range of 0.001 to 0.02 [12,13]. HA also 
has previously shown to have poor absorption onto OA articular cartilage surfaces, and thus 
functions poorly as a boundary lubricant once the boundary layer contacts have been lost 
[2,10]. There exists a need to improve the lubrication ability and retention of HA in 
viscosupplementation for the goal of better improving OA progression.  
4.1.5 HABpep-Polymer System as a Treatment  
One possible solution to the limitations of current viscosupplements is anchoring HA 
onto the load-bearing surface to improve boundary layer lubrication and help retain HA in 
the IA space for a longer period of time [10] where it can continue to have beneficially 
biological effects. The HAPpep (HA Binding Peptide)-Polymer system was developed 
previously in the lab and consists of a bifunctional PEG (thiol-PEG-SGA) core [9]. HABpep 
was linked via an amine-SGA conjugation reaction to one end of PEG while the thiol end 
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was functionalized with amine-reactive azlactone [9]. The amine-reactive azlactone 
functionality was conjugated to a collagen binding peptide so that it can interact with the 
exposed collagen of OA articular cartilage [9]. A diagram of the HABpep-Polymer system can 
be seen in Fig.4.1 [9]. With this system, HABpep binds to HA and tethers it onto the articular 
cartilage surface.  
The ability of the HABpep-polymer system to increase longevity of HA in the IA 
space was previously evaluated by IA injection into rat joints, where it was shown that use of 
the system with linear HA increased retention time 12-fold [9]. The goal of the following 
work is to screen different HABpep and PEG combinations and evaluate the preclinical 
effectiveness of the HAPpep-polymer system in reducing the progression of OA by 
modifying disease and providing symptomatic pain relief in a PTOA mouse model.  
4.2 Materials and Methods  
 
Surgically Induced OA Mouse Model  
 ACLT was performed on 10-week old C57BL/6 mice as previously described in 
Section 2.2.1.  
 
IA Injection 
Two weeks post surgery, a single 10 µL IA injection of following treatments: PBS 
(n=6), HA (20mg/mL; n=6), HABP1/Linear PEG (10mg/mL; n=6), HA+HABP1/Linear PEG 
(n=5), HABP1/Linear PEG (20mg/mL; n=3), HABP2/Linear PEG (50mg/mL; n=3), 
HABP3/Linear PEG (50mg/mL, n=3), HABP1/8-Arm PEG (50mg/mL, n=3), HABP2/8-Arm 




Histological evaluation:  
 Histological evaluation was performed as previously described in Section 2.2.1.  
 
Weight Bearing Assessment:  
 Weight bearing assessment was performed as previously described in Section 2.2.1.  
 
Hot Plate Assessment:  
  Hot Plate Assessment was performed as previously described in Section 2.2.1.  
 
Statistical Analysis 
Statistical analysis was done with a one-way ANOVA with Holm-Sidak multiple 
comparison correction in GraphPad Prism Software. P < 0.05 was considered significant.  
 
4.3 Results and Discussion  
 
 
HA Binding Peptide treated mice reduces OA progression by histological analysis  
  
 In order to determine the clinical efficacy of use of different HABpep Binding 
Systems, three different HABpep (HABP1, HABP2, HABP3) and two different PEGs 
(Linear, 8-arm) were injected IA into ACLT mouse model of PTOA. HABP1 at the low 
concentration, and HABP1+HA, showed a significant increase in proteoglycan content than 
ACLT group (Fig 1a). The HABP1+HA has a lower average OARSI score than the HABP1 
or HA groups individually thus the combination of peptide plus HA is promising (Fig 1b). 
HABP2 alone looked only slightly better than the ACLT group, but combined with 8-ARM 
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PEG showed significant increase in proteoglycan content (Fig 1a) and decrease in OARSI 
score (Fig 1b).  
Overall, the use of the HABpep-polymer system was most efficacious on reducing the 
progressing of OA with HABP2 bound to 8 arm PEG, which is proposed to be due to the 
increased retention time of HA onto the cartilage surface therefore providing boundary 
lubrication through interactions and fluid film lubrication by presence in the SF and increase 
in viscosity. In addition to mechanical functionality, HA molecule itself can have disease 
modifying activity in vivo and has been shown in vitro studies to increases proteoglycan 
content of chondrocytes from rabbit, house, and bovine [8]. It has also been shown that HA 
can suppress cartilage damage caused by fibronectin fragments which bind and penetrate 
cartilage and increase MMP levels thus suppressing proteoglycan synthesis [8]. Additionally, 
HA has also been shown to stimulate synthesis of cartilage matrix components and 
chondrocyte growth [10].  
 
HA Binding Peptide Reduces OA-Related Pain  
 
Functional pain testing was performed to screen peptides for alleviation of OA-
related pain. Mice injected with HABP1 and both linear and 8-arm PEG had significantly 
decreased latency time when put on a 55°C platform compared to other peptide and control 
groups (Fig 4.3a). Weight bearing pain test however showed that HABP2 had the most even 
distribution of weight on each hind leg (Fig.4.23). HABP1 with linear PEG was not 
significant most likely due to variability in the group, and HABP2 with 8-arm PEG was also 
not significant, although it showed a more even distribution in weight than the control groups 
(Fig.4.3b).  
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Pain relief by HA could be attributed to the effect of HA on nerve impulses and 
sensitivity [8]. Administration of HA to isolated medial articular nerves has showed decreased 
nerve activity and movement evoked activity in addition to reducing nerve impulses from an 
inflamed knee model [8]. The antinociceptive effect of HA was also seen in dose-dependent 
manner in rats, which may be due to attenuation of prosteoglandin E2 and bradykinin 
synthesis [8]. Another way HA can effect pain is by modulating the pharmacology of 
substance P, a mediator in pain through interactions with excitatory amino acids, 
prosteoglandins, and nitric oxide [8]. Increasing HA retention through use of the binding 
peptide could potentially increase binding to neuropeptides, creating a better boundary layer 
around nocireceptors thus reducing pain [10].  
4.4 Conclusions  
 In vivo screening of different peptides and PEG formulations showed that HABP2 
and 8-arm PEG showed to be the most promising HABpep-polymer system that has the 
ability to best mitigate cartilage degeneration and proteoglycan loss while reducing pain. 
This therapeutic effect shows disease modifying ability and can be attributed to the increased 
retention time in the joint that allows for additionally boundary layer lubrication and longer 
exposure of HA to the chondrocytes increasing proteoglycan secretion. HA could also 
potentially have disease modifying attributes due to its ability to interact with collagen and 
chondrocytes and thus modulating inflammatory mediators [14] such as reduction in TNF-
alpha, MMP3, and IL-1β as previously seen [8]. Additional lubrication that the system 
provides may increase binding to neuropeptides and create a boundary around nocireceptors 
causing a reduction in symptomatic pain.    
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4.5 Future Directions  
This study showed an optimal HApep-polymer system in terms of efficacy in treatment 
of OA. In the future, studies can be done to determine the appropriate dosing regime, for 
example multiple doses, of the HA injections as well as looking at long-term effects on OA 
by having longer time points. Although a retention study was already performed in the rat, it 
would also be useful to replicate the same study in the mouse model and to further 
characterize the binding properties and coefficients of the different formations.   
 




Figure 4.1 Synthesis of HABpep-Polymer Binding system [13] 
A diagram of the synthesis of the HABpep-polymer system involving a HA binding peptide, 







Figure 4.2 HA and Binding Peptide System can Reduce the Progression of OA 
(a) Representative images safranin O/methyl green from C57BL/6 mice to evaluate the 
pathological changes 4 weeks after ACLT. (PBS, n=6; HA 20 mg/ml, n=6; HABP1 10 
mg/mL, n=6; HA+HABP1, n=6; HABP1 20 mg/ml, n=3; HABP2 50 mg/ml, n=3; HABP3 50 
mg/ml, n=3; HABP1 50 mg/ml, n=3, HABP2 25 mg/ml, n=3) (b) OARSI scores from the 





Figure 4.3 HA and Binding Peptide System can Reduce Symptomatic OA-Related Pain 
(a) Response time of mice after placement onto a 55°C hotplate 4 weeks and 8 weeks after 
ACLT surgery for all treatment groups. (b) The percentage of weight placed on the operated 
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Chapter 5: Conclusion and Future Directions 
 
 
The work presented in this thesis shows three different therapeutic approaches to the 
problem of OA, a disease that affects 33.6% of those 65 years of age and older in the United 
States. A PTOA mouse model was used to evaluate each of these therapies in terms of gene 
expression, histological evaluation, and behavioral pain testing. Clearance of SCs in vitro and 
in vivo by Nutlin-3a mitigates symptomatic pain while modifying disease by generation a 
pro-chondrogenic environment with reduction of inflammatory and SASP factors resulting in 
cartilage matrix regeneration. UBM also showed the ability to reduce pro-inflammatory 
cytokines and hindered the progression of OA and reduced pain in vivo. Lastly, the HABpep-
polymer system also showed increased proteoglycan production and reduced pain. Although 
all these treatments were explored separately, the multi-faceted nature of OA calls for a 
toolbox of treatments in order to treat all aspects of the disease the most efficiently.  
It is possible that the correlated outcomes of the three explored approaches show 
relationship between lubrication, ECM biomaterial, and senescence. ACLT surgery causes 
accumulation of SCs that is partially from stresses due to mechanical dysfunction. 
Theoretically HA injections should help to further normalize this mechanical dysfunction by 
providing load-bearing properties and thus may reduce the stress stimuli causing the DDR 
and induction of SCs and therefore helping to reduce SC development. ECM injections could 
also potentially reduce SC development by lowering the cytokine levels as seen in vitro. 
Combinations of the presented treatments could be explored further in the future.    
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